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ABSTRACT 
 
As of January 1, 2012, an estimated 13.7 million cancer survivors were alive in 
the United States. The number of cancer survivors is expected to reach 18 million by the 
year 2022. Adolescent and Young Adult (AYA) cancer survivors, ages 15-39, are a 
population that experiences disparities in care, including a lack of evidence for increased 
survival.  
This thesis presents three papers, each using different methods. The first, an 
analysis of AYA breast cancer survivors’ risk factors including access to clinical trials, 
uses geographic information systems to map patients’ distance to trials and logistic 
regression to analyze demographic and clinical risk factors. The second paper applies 
quantitative and qualitative analyses in an evaluation of a public and professional 
education project on AYA survivorship. The third paper uses qualitative methods and a 
theory-based taxonomy to assess the use of behavior change theories in mobile health 
(mHealth) applications for cancer survivorship. 
The results demonstrate the multifactorial elements that impact AYA cancer 
survivorship, and suggest the need for interventions and expanded research. Additional 
research is needed to understand the unique physical and biological characteristics of 
AYAs, in particular those of AYA breast cancer survivors. The thesis illuminates the 
challenges AYA survivors experience with late effects—physical, psychosocial and 
financial—and the need for ongoing education for healthcare professionals. In 
considering the potential of mHealth applications for health behaviors change among 
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AYAs and other cancer survivors, the study articulates concerns about the limited use of 
theory in the majority of mHealth apps, and suggests the need for intervention designers 
to reflect more deeply on theoretical models.  
This thesis contributes to the field of AYA survivorship research in its evidence 
assessing risk factors including distance to cancer trials for AYA breast cancer patients, 
by identifying ongoing educational needs for both survivors and providers and by 
assessing lack of theory and potential for improvement among mHealth interventions. It 
offers suggestions for future research, policies, and program changes, including the use 
of emerging mobile technology and sensors to engage AYA survivors both as 
participants and designers of research that could improve their quality of life and 
wellbeing. 
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I. INTRODUCTION AND LITERATURE REVIEW 
 
Cancer Survivorship Chronology and Background 
Cancer survivorship is a distinct part of the cancer continuum. Despite the 
relative newness of the concept of cancer survivorship, we now have nearly 30 years of 
experience with advocacy, research, and care directed generally at cancer survivorship, 
and specifically at cancer survivors at different ages. Table 1.1 provides a brief 
chronology of major defining events in cancer survivorship. 
 
 
Table 1.1   Brief Chronology of Cancer Survivorship in the United States (U.S.)  
 
  
 Year               Activity    Areas of Importance 
___________________________________________________________________________ 
1937  National Cancer Act Established the National Cancer Institute 
(NCI) 
    
1971  National Cancer Act “War on Cancer” launched.  Number of 
cancer survivors estimated at 3 million 
    
1973  Surveillance 
Epidemiology and End 
Results Program 
(SEER)  
Initiated annual collection of cancer 
incidence and mortality data 
    
1982  Susan G. Komen 
Foundation  
Breast cancer advocacy group representing 
the largest number of survivors of a specific 
disease  
    
1986   National Coalition for 
Cancer Survivorship  
Instituted term “cancer survivor”  
    
1995  First National Congress 
on Cancer Survivorship 
Beginning of national advocacy movement 
    
1996  NCI established the 
National Office of 
Cancer Survivorship  
Office of Cancer Survivorship works with 
SEER to establish data on national cancer 
incidence and prevalence. 
    
2004   LIVESTRONG 
Foundation  
Founded in 1987, LIVESTRONG and Nike’s 
yellow arm bands make survivorship make 
survivorship a global grass roots advocacy 
effort 
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Table 1.1 Continued 
 
   
 
Year  
  
Activity  Areas of Importance  
    
2005  Institute of Medicine 
(IOM)“From Cancer 
Patient to Cancer 
Survivor: Lost in 
Translation” 
Raised awareness of late effects of cancer 
treatment; call to action for Survivorship 
Care Plans; and defined quality healthcare 
systems and policies to support survivors 
    
2007  IOM “Cancer Care for 
the Whole Patient: 
Meeting Psychosocial 
Health Needs” 
Identified failure of healthcare community to 
meet the psychosocial needs of cancer 
patients and survivors 
    
2010   American College of 
Surgeon’s Commission 
on Cancer Standards 
Issued first-ever survivor-centered 
Accreditation Standards for cancer clinics-
requiring survivorship plans, psychosocial 
assessments and patient navigation  
    
2014   American Society of 
Clinical Oncologists 
(ASCO) issues clinical 
practice guidelines 
First three of a planned series for evidence-
based clinical guidelines for cancer 
survivorship care for neuropathy, 
depression and anxiety 
 
____________________________________________________________________________________ 
 
 
When twenty-three leaders in cancer research and advocacy joined to form the 
National Coalition for Cancer Survivorship (NCCS) in 1986, one of their priority efforts 
was to find an alternative to the phrase “cancer victim.” The NCCS is credited with 
creating the definition for cancer survivor that we use today: “from the moment of 
diagnosis and for the balance of life, an individual diagnosed with cancer is a survivor” 
[1]. The First National Congress on Cancer Survivorship was in 1995, and led to the 
National Cancer Institute’s (NCI) creation of an Office of Cancer Survivorship. In 
September 1998, 250,000 citizens gathered on the National Mall in Washington, DC to 
call for increased funding for cancer research. They were joined by over a million people 
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attending over 200 events in all 50 states. Such efforts helped bring about a substantial 
increase in national research funding with a 16% increase of congressional 
appropriations to the National Cancer Institute.  
With funding from the NCI and the creation of an Office of Survivorship came 
increased scientific interest and research to document the physical, psychosocial, and 
economic effects of cancer and its treatment on cancer survivors’ quality of life and 
functional health. The Institute of Medicine (IOM published a number of reports on 
cancer care, including From Cancer Patient to Cancer Survivor: Lost in Transition [2], 
Childhood Cancer Survivorship: Improving Care and Quality of Life [3], and Cancer 
Care for the Whole Patient: Meeting Psychosocial Health Needs [4].   
The “Lost in Transition” report became the touchstone document for cancer 
survivorship among providers, advocates, and patients. By describing the shortfalls in 
U.S. survivorship care, and the lack of an evidence base for quality care of survivors, the 
report served as a research agenda. Most importantly, the IOM report recommended that 
every cancer survivor should receive a “survivorship care plan” (SCP). The description 
of the ideal SCP included information on diagnosis, surgery, and treatment, including 
chemotherapy and radiation dosages. As a shared tool between survivor and patient, 
there were recommendations for the SCP to include tailored screening and surveillance 
for late effects and cancer recurrence. The SCP would also include tailored lifestyle risks 
and tips for healthy living and information on access to psychosocial supportive care. 
The recommendations for the SCP extended into systems and policy changes, with 
information on survivors’ legal, insurance, and employment rights [2].  
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In the years from 2004 to 2006, cancer survivorship awareness became a 
worldwide phenomenon, with the iconic yellow wristband distributed and sold by the 
LIVESTRONG Foundation. As a major grassroots cancer survivorship advocacy 
organization, the LIVESTRONG Foundation, founded in 1997, helped give rise to a 
global awareness of cancer survivorship through the sales and distribution, in partnership 
with NIKE, of over 87 million yellow plastic bracelets. As of 2012, LIVESTRONG 
Foundation had raised over $500 million in donations, with approximately 84% going 
into programmatic efforts including $12.5 million for cancer control research grants to 
communities, cancer centers, and academic medical institutions [5]. 
In 2010, the Commission on Cancer of the American College of Surgeons issued 
the first-ever survivor-centered accreditation standards requiring SCPs, psychosocial 
assessments, and patient navigators. The SCP accreditation requirement, along with 
standards for patient navigation and distress monitoring were structured as phased-in 
requirements, with full standards of care to be evaluated in the 2014 accreditation 
processes. However, the path for clinics and clinicians to provide SCPs faces significant 
barriers including the lack of reimbursement under most health insurance policies and 
the challenges of pulling data from new systems for electronic medical records. And, for 
the most part, SCPs are required to be delivered only to survivors currently in treatment. 
Significant barriers exist for the development and delivery of quality care plans to post 
treatment and longer term survivors [6].  
Most recently, in April 2014, the American College of Surgical Oncologists 
(ASCO) issued three evidence-based clinical practice guidelines for care issues of cancer 
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survivors including neuropathy, fatigue and depression, and anxiety. The guidelines are 
the first in a planned series of ASCO guidelines on survivorship care that will reinforce 
among physicians and healthcare professionals the importance of caring for both 
physical and psychological needs of cancer survivors [7-9].  
Despite the increasing awareness of cancer survivorship in the United States and 
globally, it took until 2012 for the American Cancer Society to publish the first estimates 
and forecasts of the numbers of U.S. cancer survivors. An estimated 13.7 million U.S. 
cancer survivors were alive on January 1, 2012, and the number is expected to reach 18 
million by 2022 [10].  
Taking stock of nearly thirty years of history, I conclude that there has been 
significant progress in cancer survivorship, including a growing research and evidence-
base, the emergence of survivorship as a professional healthcare discipline, and ongoing 
efforts in public education, advocacy, and outreach. Yet, there are a number of 
outstanding areas of concern that remain to be addressed.  
Minding the Gap 
Prior to the 1970s, a diagnosis of cancer in childhood was nearly always fatal.  
The relative five-year survival rates among children diagnosed with cancer have 
improved from 58% in 1976 and 1977, to over 82% between 1999 and 2006.  For adults 
over 50, the relative five-year survival rates are 59%, reflecting a 22.2% decline in the 
number of deaths due to cancer from 1990 to 2007 [10]. These improvements in 
survivorship are a combined result of great strides in cancer treatment and care, as well 
as improvements in diagnostic and screening rates. But, there is a significant gap in these 
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improvements.  Rates of overall survival for adolescent and young adults (AYAs), ages 
15-39, diagnosed with cancer have not improved significantly for over 30 years, and 
until recently, they were a relatively neglected population group. So much so, that in the 
first Surveillance, Epidemiology and End Results (SEER) monograph and study of AYA 
cancer epidemiology in 2006, AYAs were considered a population that experienced 
significant disparities in care [10]. 
One of the reasons for relative neglect is the size of the AYA population. Only a 
small number, roughly 5%, of those diagnosed with cancer are young adults. This 
equates to just over 70,000 AYA patients per year. Over the past 10 years, the gap in 
survival for AYAs in comparison to older and younger cancer patients has become a 
focus for both U.S. and international research, including detailed reports from the NCI 
on AYA cancer incidence and epidemiology. Seminal AYA survivorship and care 
reports include two NCI Progress Review Groups, one in 2006 and a second in 2012, 
and a set of National Comprehensive Cancer Center Network Guidelines [10-13]. Most 
recently, the IOM collaborated with the LIVESTRONG Foundation in a report, 
Identifying and Addressing the Needs of Adolescents and Young Adults with Cancer: A 
Workshop Report [14].   
While it is reassuring to note recent progress in some of the AYA cancers, 
including acute leukemias, breast cancer, and malignant melanoma, there is a lack of 
statistically significant evidence for increased survival among the majority of cancer 
types occurring in AYAs. Researchers speculate that the lack of improvement in AYA 
survival may be due to a combination of factors including: 1) lack of available clinical 
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trials for this age group and low enrollments; 2) lack of medical insurance; 3) poor 
access to medical care both at initial diagnosis and follow on; and 4) attitudes and 
behaviors of young adults including a sense of invincibility, being too busy with work 
and education, and risk taking behaviors [15-17].  
While more than 80% of AYA survivors will live beyond the first five years after 
treatment, they are also likely to develop serious morbidities, or will die prematurely.  
Cancer continues to be the leading cause of disease related death for AYAs, after 
accidental death and suicide [18,19]. AYA cancer survivors who were diagnosed during 
adolescence have an increased risk of death beyond five years as compared with other 
cancer survivor populations. This excess mortality is caused by cancer recurrence, 
subsequent neoplasms, and cardiovascular and lung disease that are the results of the 
original cancer treatment.  Racial, ethnic, and socio-demographic factors, including 
geographic location and distance from cancer care and clinical trials, and lack of 
insurance also impact AYAs survivorship [20, 22].  
One of the reasons AYA cancer survivors are an important group to study is that 
they, as well as childhood cancer survivors, live longer past treatment and thus, the 
specter of late effects looms larger. Oeffinger et al. reported that by 30 years past initial 
diagnosis and treatment, the incidence of chronic health conditions among AYA 
survivors was 73%, with a cumulative incidence of 42% for severe, disabling life-
threatening conditions or death [16]. These severe late effects of treatment include breast 
cancer, male and female after chest radiation, and cardiomyopathy after anthracycline 
chemotherapy [21, 22]. 
  8
AYA Cancer Care and Survivorship Interventions 
The 2013 IOM/LIVESTRONG workshop report on AYA oncology notes, 
especially, the lack of information regarding research and the need for an evidence base 
to guide policies and practice in order to determine what surveillance for cancer among 
AYAs and AYA survivors is appropriate and needed [15]. This includes the need to 
identify characteristics that distinguish the unique biological and genetic characteristics 
of certain AYA cancers, including breast cancer, which may warrant increased support 
for inclusion of AYAs into cancer research trials. Chapter II in this dissertation 
addresses this concern by examining demographic and diagnostic risks associated with 
later diagnosis among Texas AYA breast cancer patients, including distance to breast 
cancer clinical trials appropriate to their stage of diagnosis. An initial comparison is 
made between national and Texas populations’ AYA breast cancer incidence by race and 
ethnicity. I used the SEER database and the Texas Limited Use database, both of which 
reside on the SEER system. Texas Cancer Registry (TCR) data was requested for 
individual AYA breast cancer patients’ diagnostic and demographic information, 
including the latitude and longitude of their residence at time of diagnosis. This data was 
used to explore risk factors for AYA breast cancer patients being diagnosed at later 
versus earlier stages. The study is innovative in that it includes distance from breast 
cancer trials for which the patients would be eligible as a possible risk factor. 
Chapter III considers the need for increased professional and patient education as 
well as focused education and engagement with AYA survivorship advocacy efforts 
through a mixed methods evaluation. Cancer survivorship is increasingly seen as a 
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chronic condition that requires attention for surveillance and screening, not only for 
physical late effects but also psychosocial late effects. Education and training for self-
management of cancer survivorship as a chronic disease is needed for survivors, family 
members, and caretakers. Because of the high incidence of late effects among AYA 
cancer survivors, the knowledge sharing and communications that need to occur during 
the transition period from cancer care into community care is especially important. Not 
only are AYA survivors likely to need developmentally appropriate psychosocial care, 
they also need extensive follow-on surveillance by a physician who is educated and 
aware of the likely chronic conditions and late effects that may occur in these patients.    
There are numerous barriers for AYA survivors receiving adequate follow-up 
care including lack of insurance and funds, lack of awareness of the specifics of their 
treatments, and lack of relationships with community providers. On the provider side, 
many community healthcare professionals, both nurses and physicans, lack the 
knowledge and experience to take on the care of AYA cancer survivors, many of whom 
are medically complex. In some cases, there may be unwillingness to care for AYA 
survivors, both as a result of lack of knowledge and the stress of fitting them and their 
needs into the tight schedules of a busy community-based practice or clinic. This 
evaluation considers the perceptions of the benefits, value, and sustainability of a grant-
funded effort to provide AYA cancer survivorship education among healthcare 
professionals, cancer advocates, and AYA survivors.   
AYA cancer survivors, as is true of all cancer survivors, can benefit from 
lifestyle and behaviour changes (e.g., not smoking, increasing physical activity, and 
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improving their diet and nutrition intake) linked to improved health related quality of 
life. Interventions to support behaviour changes among AYA survivors include the use 
of Internet and mobile technologies to increase engagement and social support. In 
addition to health behaviour change interventions, mobile applications offer 
opportunities to provide increased access to education and tools for AYAs to be aware of 
late effects of their care and treatment. There are now many mobile applications 
associated with cancer care, treatment, and survivorship, both for professionals and 
patients. While less than a handful of mobile applications for cancer survivors are 
specifically focused on AYAs, these tools may provide cost effective and easily 
adaptable interventions to support behaviour change and improved quality of life for 
AYAs and other cancer survivors. Unfortunately, while there are an increasing number 
of mobile apps for cancer, the theoretical basis used in the apps design and development 
is frequently unknown. Chapter IV provides an assessment of cancer survivor apps with 
a focus on the extent to which they are designed and developed based in health and 
communication theories.    
Research Contribution to Public Health and Practice 
Recognizing the need to better understand the specific needs and risks of AYA 
cancer survivors, and developing interventions tailored to address the health disparities 
that affect this group is a worthy challenge. Over the past few years, progress has been 
made in closing the gaps in AYA care and survivorship, but many challenges remain in 
making improvements in the care and outcomes of this unique group of cancer survivors.  
Much of the effort in AYA research has been on understanding their specific biological 
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and psychosocial risks and needs. To date, few researchers or healthcare practitioners 
have taken the steps to translate AYA research into theory and evidence-based 
interventions. Table 1.2 provides a schema of my research questions, methods, and 
analytical strategies. I begin in Chapter II with an innovative approach to clarify the risks 
and barriers faced by AYA breast cancer patients in Texas, including distance to 
appropriate cancer clinical trials. In Chapter III, I move from risk assessment into an 
evaluation of professional and patient education programming for AYAs. This mixed 
methods evaluation is a theory-based, primarily qualitative analyses of the value, 
benefits, and ongoing barriers in delivering educational programming and health 
behaviour based interventions to AYA survivors, community healthcare providers, and 
cancer advocates.  In the final study, in Chapter IV, I examine a range of cancer 
survivorship-related mobile apps to determine the extent to which they incorporate 
health behaviour change and communication theory elements.   
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Table 1.2 AYA Survivorship Research Questions, Approaches and Analytical 
Strategies  
 
 
 Research      Population          Methods/Analytical  
 Question       and Setting                    Strategies  
 
Chapter II  
What are the demographic and 
diagnostic risks associated with 
later versus earlier stage at 
diagnosis for Texas’ AYA breast 
cancer patients?   
 
Does distance to breast cancer 
clinical trials matter?  
SEER and Texas AYA breast cancer 
population (2005-2009) 
 
4153 Texas breast cancer patients, 
ages 15-39 (2005-2009) 
SEER*Stat for Breast 
Cancer Rate Incidence by 
Race and Ethnicity 
 
ESRI ArcGIS 10.1 for 
Mapping and Network 
Analysis  
 
Logistic Regression for 
Odds Ratios of Risk 
Factors using Stata 10.1  
 
Chapter III  
To what extent did the ACCESS 
AYA educational program for 
healthcare professionals, AYA 
cancer survivors and cancer 
advocates increase health 
literacy, communications and 
understanding of AYA survivors?  
 
What common barriers do AYA 
survivors experience?  
 
What opportunities and 
challenges exist for sustaining and 
expanding AYA survivorship 
education programs?  
 
 
Telephone surveys of  
19 stakeholder participants in the 
ACCESS AYA project using semi-
structured interview guides.  
 
Brief survey analysis, 
First and Second Cycle 
Coding of Stakeholder 
Interviews based on a 
theoretical framework.  
 
Atlas.ti used for coding by 
two independent coders.  
 
 
Chapter IV 
Are health behavior change 
theories and behavior change 
frameworks being used in 
mHealth apps?  
 
What theories should app 
designers draw upon in designing 
apps for cancer survivors?  
 
What behavior change techniques 
may be effective in delivering 
mHealth mobile interventions?  
 
 
mHealth apps for cancer 
survivorship for IOS platform apps 
found on the Apple App store and 
Android apps found on Google Play 
web store. 
 
 
Qualitative analysis based 
on the taxonomy of health 
behavior change theories 
and frameworks by 
Mitchie et al. [23].   
_____________________________________________________________________ 
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Cancer survivorship is a relatively young field of research. The growing evidence 
base and research on improvements in care and practices that support improvements 
among this relatively small population has the potential to provide benefits and value to 
the larger and ever growing population of older cancer survivors. In this dissertation, I 
contribute to the expanding research base of understanding the risks and barriers to 
healthy survivorship among AYA cancer survivors. I further identify innovative 
practices for survivor and healthcare professional education including use of mHealth 
applications that have implications for all cancer survivors as well as for self-
management of other chronic diseases. I also identify research and intervention 
challenges and opportunities to support practice, system, and policy changes to improve 
the quality of life and care for this unique population of young cancer survivors. 
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II. AYA BREAST CANCER IN TEXAS: RISK FACTORS FOR DELAYED 
DIAGNOSIS 
 
Background 
Breast cancer is one of the most commonly diagnosed cancers among adolescent 
and young adult (AYA) females, ages 15-39 years of age [24]. In the U.S., 
approximately 14% of all AYA cancers diagnosed in females are breast cancer. Despite 
their small numbers, AYAs represent approximately 7% of all female breast cancer 
diagnoses [24, 25]. 
Younger women are more likely to be diagnosed at later stages and higher grades 
of breast cancer, due, in part, to cancer being unexpected at younger ages and screening 
norms that begin at age 40 or older. Breast cancer in younger women is considered 
aggressive, and just being younger is considered a negative predictor for survival. Being 
diagnosed at a younger age has a high correlation with breast cancer recurrence and 
being diagnosed with both local and distant recurrence, including contralateral breast 
cancer recurrence [26].  
Recent research suggests that AYA breast cancer may be distinctly different from 
that of older women, clinically, etiologically, and genetically [27]. AYA women 
diagnosed with breast cancer have larger proportions of cancers with lower estrogen 
receptor (ER) positivity and overexpression of human epidermal growth factor receptor 
2 (HER2) and triple negative subtypes (24, 27).  
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Family history and genetics may also be factors in younger women’s diagnoses.  
A woman under age 35 has a 9.4% likelihood of having BRCA1/2 genetic mutation as 
compared to the population average of 0.2% [28]. These statistics suggest the need for 
increased surveillance for young women diagnosed with breast cancer, and strong 
consideration for increased research and enrollment of young women diagnosed at both 
early and later stages of breast cancer into breast cancer research trials.  
The documented lack of improvement in overall AYA cancer survival is 
attributed to a combination of factors. In addition to biological and genetic factors, other 
issues have been identified including lack of access to care and underinsurance.  Further, 
lack of social support and the unique stage of life issues of entering adulthood, and 
starting jobs and families are risk factors that need to be taken into consideration when 
considering cancer care and survivorship among the AYA population [29]. 
Additionally, the lack of AYA enrollment and participation in clinical trials has 
been cited as critical factors in making progress in AYA cancer research [29]. Yet, 
relatively few AYAs are enrolled in clinical trials, in part due to the unique socio-
demographic and psychosocial characteristics of young adults, but also because 
diagnosing physicians seldom refer these patients to trials [30]. In the U.S., clinical trial 
enrollment among pediatric cancer patients is generally high, near, or at 50%, but 
enrollments fall as age increases, with approximately 10% of patients ages 15 to 19 
years, and only 1% to 2% of patients ages 20 to 39 years enrolling in clinical trials [31].  
In order to better understand the factors associated with survivorship among AYAs 
diagnosed with breast cancer, I wanted to examine the importance of access to care and 
  16
clinical trials among AYAs. Texas is an ideal area to examine these questions because of 
its diverse racial and ethnic population, with a median age of 33 for both sexes [32]. 
While the actual number of breast cancer trials open and accruing may change on a daily 
basis, Texas generally ranks among the top three states  (i.e., California, New York, and 
Texas) with the largest number of breast cancer trials [33]. The purpose of this research 
study was to explore risk factors that may affect Texas’ AYA breast cancer patients 
being diagnosed at early versus later stages of cancer, including the distance to breast 
cancer clinical trials. By doing so, I hope to add to growing research on AYA cancer 
care and survivorship and to support efforts to improve access to clinical trials for AYA 
breast cancer and other AYA cancer patients. 
Data and Methods 
Data Sources and Population 
To assess Texas’ AYA breast cancer incidence and comparisons to national data, 
I used the National Cancer Institute’s SEER data [34] and the epidemiological analysis 
computer program, SEER*STAT [35]. 
The analyses covered the period from January 1, 2005, through December 31, 
2009. I accessed the SEER 18-Registry database, which includes cancer statistics on 
approximately 28% of the U.S. population. I was granted permission from the Texas 
Cancer Registry (TCR) to use the Texas Limited-Use Database, also available on 
through the data sets for SEER*STAT [35].  
In addition to the Limited-Use Database for Texas, we obtained individual 
patient incidence and mortality data from the TCR for 82,643 AYAs diagnosed in Texas 
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from 1995-2009 (36).  From this data, I selected 4,630 breast cancer patients, 15-39 
years of age during the period from January 1, 2005 through December 31, 2009.  
Included are all female residents diagnosed with in situ and invasive breast cancer 
(International Classification of Disease for Oncology, 3rd Edition, ICD-0-3) for site 
codes C500 through C509. The data was requested under an approved Institutional 
Review Board Protocol (IRB) 13-022 from the Texas Department of State Health 
Services and IRB Protocol 2013-0233M from Texas A&M University. Individual 
consent was not obtained, as the data used was acquired under Texas’ state-mandated 
cancer registry data process.   
Measures 
For each breast cancer case, we requested information routinely gathered by 
clinical cancer registrars from the patient’s medical record including sex, age at 
diagnosis, race/ethnicity, and payer at diagnosis. The TCR patients’ tumors stage at 
diagnosis was recorded by the TCR using the SEER Summary Stage coding (0=in situ; 
1=localized; 2=regional by direct extension only; 3=regional to regional lymph nodes 
only; 4=regional direct extension and regional lymph nodes; 5=regional, not otherwise 
specified; 7=distant Metastasis; 8=not applicable; 9=unstaged, unknown or unspecified 
(note that there is no stage 6). Tumors that were in situ and localized stages 0 and I were 
considered “Local” while tumors diagnosed at stages II through V were considered 
“Regional” and those diagnosed at stage 7 were classed as “Metastatic.” The grades of 
cancer were based on the ICD-03 system and were classed as follows: 1=Well 
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differentiated; 2=Moderately differentiated; 3=Poorly differentiated; 4=Undifferentiated, 
5-8 = Cell types; and 9=Unknown/Undetermined.   
The TCR patient data request included items routinely added to the patient data 
during inclusion into the registry as a cancer patient. These are fields that have been 
developed and submitted to the National Program of Cancer Registries and/or the North 
American Association of Central Cancer Registries to ensure that any data released by 
TCR has met a protocol of quality standards. The TCR constructed data fields requested 
included 5- year age groups, Rural/Urban Beale continuum codes (categorized as Metro-
1 for Codes 0-3 and Non-Metro=0 for Codes 4-9), patient residence latitude and 
longitude, vital status at last contact (e.g., dead=0, alive=1), and SEER specific cause of 
death.   
The SEER summary stage classification was selected as a binary dependent 
variable in our logistic regression analysis with the patients diagnosed at local stages 
coded as “0” and the combined group of patients coded as regional or metastatic as “1.” 
On this basis, 472 cases for which the patient’s summary stage was unknown were 
excluded from the total of 4,630 breast cancer patient records. All patient geocoding was 
done by the TCR, and the database received from TCR included the latitude and 
longitude for each patient. Five cases had to be excluded from the database during the 
Geographic Information Systems (GIS) Network analyses due to problems with 
addresses or lack of direct roadway access (e.g., the patient lived on an unpaved road). 
The resulting study population included 4,153 women, ages 15-39 diagnosed with breast 
cancer in Texas during the study period 2005 to 2009.  Due to the low numbers of 
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metastatic patients (n=275, 6.62%) in the summary stage groups, this group was 
combined with patients diagnosed at regional stages. As a result, the dependent variable, 
summary stage, was defined in two categories: “Early Stage” for patients staged as in 
situ and local (n=2,238) and “Later Stage” for patients staged as regional and metastatic 
(n=1,915).  
BreastCancerTrials.org, a non-profit foundation that provides patient matching 
services for breast cancer trials, located at University of California at San Francisco 
provided data, including latitude and longitude, for 23 trials that were open and accruing 
Early Stage breast cancer trials at 67 locations in Texas. There were 52 Late Stage Trials 
open at 93 locations in Texas. Only treatment trials were included, no supportive care 
trials were provided for matching. The 2,238 patients classified as Early Stage would 
most likely have been eligible for trials with inclusion criteria for ductal carcinoma in 
situ, neoadjuvant trials for drugs given prior to surgery, biological therapies, types of 
radiation therapy, or new surgical techniques. The 1,915 patients classified as Late Stage 
were matched to Late Stage trials with a range of inclusion criteria, some similar to the 
early stage, such as biological therapies and radiation therapy. Many of the later stage 
trials inclusion criteria specified histologically confirmed diagnoses of breast cancer 
based on pathology report of primary, regional or metastatic breast cancer. Both lists of  
trials and their locations are provided in Appendix A. The breast cancer trials were 
situated at various types of locations including American College of Surgeons accredited 
breast centers, community oncologist offices and academic and National Cancer Institute 
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designated cancer centers.  The trials were geocoded based on the trial site cancer center 
or clinic physical address and the geocoding-match rate for both sets of trials was 100%. 
In order to assess the distance to open and accruing breast cancer trials ESRI 
ArcGIS software (Version 10.1) Network Analyst was used to provide spatial analysis 
for the closest facility by either travel time or roadway distance [37]. For each patient in 
the database, roadway miles were mapped to the nearest breast cancer trial for which the 
patient would most likely be eligible. The Network Analyst tool created an estimated 
shortest distance to the nearest facility with an appropriate trial for each patient. For each 
patient classified as Early Stage, the shortest distance to an Early Stage trial for which 
they would most likely meet inclusion requirements was calculated. Similarly, the 
distances in roadway miles required for patients classified as Late Stage were mapped to 
the closest Late Stage trial location. One Early Stage trial was open at the Brooks Army 
Medical Facility in San Antonio, Texas, and The Audie L. Murphy VA Hospital, also in 
San Antonio, offered one Late Stage trial. These trials were only open to members of the 
military and veterans with military insurance (i.e., Tricare or Military insurance). There 
were 32 patients classified as Early Stage with Tricare or Military insurance who 
matched to the Early Stage Trial at Brooks Army Medical Facility in San Antonio, 
Texas. There were 20 patients classified as Late Stage whose payer at diagnosis was 
listed as military or Tricare. These Late Stage patients were matched to the trial at Audie 
L. Murphy VA Hospital in San Antonio, Texas. Once the miles to breast centers and 
trials were calculated for each patient, the mileage data for each patient was included 
into the database by matching each patient’s geo-unique number from the TCR dataset to 
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the results from the network analysis. The geo-unique number is associated with the 
patient data when the patient’s address is geocoded at the TCR.  
Statistical Methods  
For the SEER*Stat analyses of AYA breast cancer incidence rate, I accessed 
both the SEER 18-Registry database, which includes cancer statistics on approximately 
28% of the U.S. population, and the TCR Texas Limited-Use Database. The incidence 
rates for both data sets were run using the SEER*Stat rate analysis system for the 
following selections: 
 Age at Diagnosis for age groups 15-19 years, 20-24 years, 25-29 years, 30-34 
years, and 35-39 year olds; 
 Sex was designated as “Female only;” 
 Years of Diagnosis -2005-2009; 
  Race and Ethnicity as specified; and 
 Site and Morphology Site Recode from the 1CD-03/World Health Organization 
2008 for “Breast.” 
In preparing for the individual patient analyses, the data were summarized for 
descriptive statistics using frequencies and percentages. Bivariate analyses were 
conducted for patient demographic characteristics and clinical characteristics and 
associated distance to clinical trials distance as categorized (e.g., 0-<45 miles, 45 -100 
miles, 101-200 miles, and >200 miles). This range of distances were calculated based on 
the mean distance to clinical trials for the majority (73.87% of the AYAs were living 
within 45 miles of a trial when diagnosed) of the AYA subject population, using 45.5 
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miles as the base line. The second distance level extending beyond 45 miles to 100 miles 
takes into consideration the significant distances between major population centers in 
Texas, and the assumption that many Texans routinely drive between 100-200 miles 
between major cities. The Pearson’s chi-square goodness of fit test was used to test 
whether the observed proportions for categorical variables differed from hypothesized 
proportions. Additionally, in preparation for the logistic regression, each variable was 
tested as an independent variable in separate logistic models using binary dependent 
variable for summary stage. A likelihood ratio test was computed to assess overall 
significance of multiple variables. We used the cut point of a p-value <. 25 to determine 
which variables would be included in the analyses.    
In order to evaluate differences in the summary stages (i.e., Early Stage as 
compared to Late Stage) by the clinical and demographic predictor variables, logistical 
regression was used to calculate Odds Ratios (OR) at the associated 95% confidence 
intervals (CI). The final fitted model included vital statistics, type of insurance payer at 
diagnosis, Non-Hispanic/Hispanic ethnicity, grade of cancer, and the patient’s distance 
to the appropriate associated stage of breast cancer trials (e.g., Early Stage or Late Stage 
Trials). The model was checked and tested for normality among the residuals. Model 
testing included tests for homoscedasticity, link testing for model specification, 
goodness of fit, overdispersion, skewness and kurtosis, Variance Inflation Factor (VIF), 
and influential observations. We made no adjustments to our final fitted model as it 
displayed no issues for either homoscedasticity or goodness of fit tests and there was no 
skewness or kurtosis. The VIF score, which was not considered severe with a score 
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under 10 (i.e., 1.05), was used to test for issues of multicollinearity in the models.  Also, 
there were no significant influential observations according to a Cook’s D test. All 
model tests were conducted using Stata version 12.1 (Stata Corporation, College Station, 
TX).  
Results 
To begin the exploration into AYA breast cancer, it is helpful to compare Texas 
AYA breast cancer incidence rates to U.S. national incidence rates, including differences 
by race and ethnicity. This information is useful in understanding and interpreting the 
risks associated with being classified at Early Stage versus Later Stage. Table 2.1 
provides a comparison of Texas’ AYA cancer incidence to U.S. AYA cancer incidence 
by race, including comparisons of White, African American, Native American and 
Alaskan Natives, and Asian American/Pacific Islanders.  Non-Hispanic and 
Hispanic/Latina/Spanish ethnicity cancer incidence rates are also shown.  
 
Table 2.1. Comparison of U.S. and Texas’ AYA Breast Cancer Incidence (2005-  
2009) 
 
Population 
Characteristic 
Sample Size Age-Adjusted 
Incidence Rate 
95% Confidence 
Interval 
 
Race   
U.S. AYAs (SEER)          14,074         20.8 20.4-21.1 
TX AYAs  4,445         22.6 21.9-23.2 
 
U.S. White 
 
10,175 
              
        20.6 
  
20.2-21.0 
TX White    3431         21.7 21.0-22.5 
 
U.S. Black 
 
2,215 
              
        24.6 
 
23.6-25.7 
TX Black    722         27.4 22.8-26.6 
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Table 2.1. Continued  
 
Population 
Characteristic 
Sample Size Age-Adjusted 
Incidence Rate 
95% Confidence 
Interval 
____________________________________________________________________________ 
 
American Indian/ 
Alaska Native 
 
 
     92 
  
 
         8.6 
  
 
  6.9-10.5 
TX America 
Indian/Alaska Native 
     23        11.2   7.1-16.8 
 
 
U.S. Asian/Pacific 
Islander 
 
 
 1,469 
 
 
       18.0 
 
 
17.1-18.9 
TX Asian/Pacific 
Islander 
   172        16.3 14.0-19.0 
 
Ethnicity 
   
U.S. Non-Hispanic 
White 
11,457  
       22.2 
 
21.8-22.6 
TX Non-Hispanic 
White 
  3017        24.9 24.0-25.8 
 
U.S. Hispanic/Latino 
 
  2617 
 
       16.8 
          
15.5-16.8 
TX Hispanic/Latino   1428        18.7 17.8-19.7 
_____________________________________________________________________________ 
Note: Rates are per 100,000 and age-adjusted to the U.S. Standard Population (19 age groups 
Census P25-1130) Confidence Intervals (Tiwari mod) are 95% for rates. Rates for unknown 
race/ethnicity not calculated.  
 
 
  
In considering the comparisons of Texas AYA breast cancer population with the 
SEER U.S. data, the overall Texas AYA population age-adjusted incidence rate of 22.6 
(CI 21.9,23.2) is slightly higher. The Texas Black/African American AYA breast cancer 
incidence rate is higher at 27.4 (CI 22.8,26.6) as compared to the SEER U.S. 
Black/African American incidence rate of 24.6 (CI 23.6, 25.7). The Texas Hispanic 
Latino numbers are more than half (55%) the size of the SEER US. Hispanic/Latino 
population, which represents 28% of the U.S. population. The Texas Latino/Hispanic 
AYA breast cancer incidence rate is 18.7 (CI 17.8,19.7) as compared to the SEER Latino 
Hispanic AYA breast cancer incidence of 16.8 (CI 15.5,16.8). Descriptive statistics from  
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the TCR dataset for Texas AYA cancer patients from 2005-2009, are shown in Table 
2.2.  
 
 
Table 2.2. Descriptive Statistics for Texas’ AYA Breast Cancer Patients (2005-
2009) 
___________________________________________________________________________ 
      Variable/Descriptor                 Number of       Mean Percentage/ 
             Observations    Frequency 
____________________________________________________________________________  
Age at Diagnosis 4,153  34.9   
years 
N/A 
Vital Statistics 
  Alive 
3,656  88.03% 
  Dead     497  11.97% 
 
Beale Metro Code* 
  Metro 
  Non-Metro  
 
3,806 
   347 
  
91.64% 
8.36% 
 
Race 
  White   
  Black 
  American Indian/Alaska 
Native 
 Asian/Pacific Islander   
Other 
 
        3,223 
  675 
    12 
    
162 
             81 
  
77.61% 
16.25% 
0.29% 
 
3.90% 
1.95% 
 
Non Hispanic 
Hispanic 
 
2,882 
1,331 
  
69.95% 
32.05% 
   
Summary Stage of Cancer 
  In situ/local 
  Regional 
  Metastatic 
2,238 
1,640 
           275 
 53.89% 
39.49% 
   6.62% 
   
Distance from Trials (miles) 4,153  45.55 miles        
_____________________________________________________________________________ 
 
 
The 2,238 Early Stage patient population’s dispersion across Texas is shown in 
Figure 2.1. The results of the ArcGIS Network Analysis showing the distance for 
  26
patients to the nearest Early Stage trials are shown in Figure 2.2. There were 23 open 
and accruing Early Stage breast cancer clinical trials located at 67 different sites in 
Texas. The 2,238 patients classified as Early Stage would most likely have been eligible 
for this type of trial. The majority of the 67 Early Stage breast cancer trial locations were 
in the larger urban areas of Texas with 28 in Houston and 21 in the Dallas/Fort Worth 
metro area. San Antonio was home to six trials and the Austin metro area to 10 trials.  
The other trials were spread across Texas with two each in Laredo and Lubbock and the 
remaining four in smaller communities. To reach the nearest trials in Lubbock, Texas, 
patients living in the El Paso using major roadways would be required to drive out of 
Texas to and into New Mexico to reach Texas trial locations. 
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Figure 2.1 Early Stage AYA Patients and Roadways to Trials 
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Figure 2.2 Network Analysis for Early Stage Trials 
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Figure 2.3 shows the dispersion of the 1,915 patients classified as Late Stage 
across the state of Texas. Figure 2.4 shows the roadway network analysis for the Late 
Stage patients’ travel to the nearest of the 93 locations for the 52 Late Stage trials. 
Similar to the early stage trials, the Late Stage breast cancer trials were primarily in the 
Houston and Dallas areas with 34 trials in various cancer centers in the Houston and 
Galveston region and 37 trials in the Dallas/Fort Worth Metroplex. San Antonio had six 
late stage trials across five locations in that city; one location in Tyler, Texas had four 
late stage trials. The remainder of the trials were located in smaller cities including 
Austin, Temple, and Abilene among others.  
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Figure 2.3 Late Stage Patients and Roadways to Trials  
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Figure 2.4 Network Analysis for Late Stage Trials 
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Table 2.3 provides bivariate analyses of multiple demographic variables as 
compared to distance from clinical trials. The variables including age group at time of 
diagnosis, vital statistics, metro-versus non-metro residency, race, Hispanic/Non 
Hispanic ethnicity, and type of insurance provider at time of diagnosis. Of these, the 
variable age group was non significant with p-value of 0.792, which suggests the need 
use age at diagnosis as a continuous variable in the regression analysis to obtain greater 
age differentiation. As might be expected, the percentage of breast cancer diagnoses 
among AYAs was greatest among the older AYAs with 32.4% (N=993) in the 31-35 age 
group and 54.4% (N=1,669) in the 36-39 year age group.  
Type of insurance at diagnosis was explored based on prior research suggesting 
insurance status as a risk factor in breast and other cancer diagnoses. [29] Among the 
Texas AYA breast cancer patients, 55.5% (N=2,306) had some type of coverage, 
including private and public insurance, at diagnosis. The TCR data indicated that 7.4% 
(N=309) reported no insurance and/or provided some level of self-pay. Approximately 
37% of the participants from the TCR database were reported as “insurance status 
unknown.” Whites dominated the racial groups with 77% of the sample populations. The 
TCR codes for Spanish/Hispanic origin were categorized into two groups: Non-Hispanic 
Non-Spanish with 67.95% (N=2,822) and Spanish, Mexican, South/Central American, 
and Other Hispanic, including those with Spanish surnames at 32.05% (N=1,331) of the 
sample. 
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Table 2.3 Associations Between Travel Distance to Breast Cancer Trials and   
Risk Factors  
_______________________________________________________________________															
	Demographic		 							Distance	Via	Roadway	to	Nearest	Breast	Clinical	Trial	
	Variables	
________________________________________________________________________________________________________	
 <45 Miles 
(N=3068) 
45-100 
Miles 
(N=500) 
101-200 
Miles 
(N=416) 
>200 Miles
(N=169) 
N=4153  p-value
 
  Age Group (yrs.)  
      
0.792 
  15-19     .17%  0.00%   0.02%   0.02% 9  
  20-25   1.66%  0.19%   0.29%   0.12% 94  
  26-30   7.90%  1.32%   1.16%   0.43% 449  
  31-35 23.96%  4.02%   3.06%   1.54% 1,353  
  36-39 40.19%  6.05%   5.49%   1.95 % 2,248  
 % total 
   
Vital Statistics  
73.87% 12.04 10.02%   4.07% 4,153  
 0.597 
  Dead (all causes) 11.70% 13.80% 13.54% 12.43% 497  
  Alive  88.30% 86.20% 86.46% 87.57% 3,656  
 
  Metro1  
      
<0.000 
  Metro  99.12% 62.20% 71.15% 93.49% 3,806  
  Non-Metro    0.88% 37.80% 28.85%   6.51% 347  
       
  Insurance       <0.002 
  Insured  55.60% 53.80% 56.73% 56.22% 2,306  
  Uninsured/selfpay    7.20%   6.00%   7.69% 15.38% 309  
  Unknown Ins.  37.19% 40.20% 35.58% 28.40% 1,538  
 
  Race  
     <0.000 
  White  74.151% 82.00%  89.18%  98.82% 3,223  
  African American 18.45% 14.80.%    8.16%   0.59% 675  
  American Indian    0.33%      .20%     0.24%   0.00% 12  
  Asian/Pacific Isl.      4.66%   2.20%   1.68%   0.59% 162  
  Other/Unknown   2.41%   0.80%   0.72%   0.00%           81  
 
 Hispanic  
Ethnicity2 
       
<0.000 
  Non-Hispanic  71.61 79.80% 51.20% 7.69% 2,282  
  Hispanic  28.39% 20.20% 48.80% 92.31% 1,331  
_______________________________________________________________________________________________________			
1.	Metro	areas	are	based	on	the	Rural	Urban	Continuum	Beale	Code	2003		
2.	Hispanic	ethnicity	includes	those	with	Hispanic	surnames.	
 
Table 2.4 shows the associations between cancer diagnostic factors and the 
distance of the patient’s place of residence at time of diagnosis to breast cancer trials.  
As distances from trials increased beyond 45 miles, so did the proportion of patients 
  34
diagnosed with regional or metastatic cancer, with 60.4% (N=258) of those living 
between 45-100 miles from a cancer trial and 57.9% (N=98) more than 200 miles from a 
trial. The exception from this trend was for those women living 101-200 miles from a 
trial; among this group only 37.9% were diagnosed at later stages. Tumor grade of the 
AYA breast cancer patients was somewhat evenly dispersed over the distances from 
trials. Sequence of tumors for the AYA cancer patients was non-significant, with a p-
value of .684, ruling out its consideration as a variable in the logistic analysis. 
 
 
 
Table 2.4 Associations Between Cancer Diagnostic Factors and Distance From 
Clinical Trials 
___________________________________________________________________________ 
Cancer Diagnosis Factor    Distance Via Roadway to Nearest Clinical Trail 
_____________________________________________________________________________________ 
 
Cancer Diagnosis 
Factors 
<45 Miles
(N=3068) 
45-100 
Miles 
(N=198 
101-200 
Miles 
(N=460) 
>200 Miles 
(N=375) 
      N=         p-value
      
Summary Stage 3,068        500 416 169 <0.000 
In Situ/Local       55.80% 39.6%  62%     42%  
Regional/Metastatic   44.23% 60.4% 37.98% 57.99%  
 
Tumor Grade1      0.028 
Well Differentiated 6.03% 5.80% 4.33% 5.92% 242  
Moderately 
Differentiated 
25.88% 28.80% 24.04% 26.04% 1,082  
Poorly Differentiated 50.46% 50.60% 52.64% 53.25% 2,110  
B-Cell/T-Cell & other 
Cell Types 
2.12% 3.60% 5.05% 2.37% 108  
Undifferentiated     15.51% 11.20% 13.94% 12.43% 611  
 
Sequence 
      
0.684 
One Primary  90.68% 89.20% 93.03% 88.76% 3,765  
First of 2 or more 4.11% 5.60% 2.40% 6.51% 175  
2nd of 2or more 4.95% 5.00% 4.33% 4.33% 203  
Unspecified/Other  0.26% 0.00 0.00 0.00 10  
 
1.Tumor Grade is the degree of abnormality of cancer cells based on ICD-03 
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A logistic regression analysis model was built to compare AYA women 
diagnosed at in situ or localized breast cancer as compared with AYA women diagnosed 
at regional and metastatic summary stage (Table 2.5). Among the demographic 
variables, not having insurance, being of Hispanic/Latina ethnicity, and being African 
American were significantly associated with being diagnosed at a later summary stage 
(i.e., regional or metastatic).    
 
 
Table 2.5. Texas AYA Breast Cancer Characteristics Associated With Being 
Diagnosed at a Later Versus Earlier Summary Stage  
____________________________________________________________________________ 
Characteristic      Odds Ratio         p-value        95% CI 
 
 
Insurance at Diagnosis  
  Insured 
  Not Insured/Self Pay 
  Insurance Status Unknown 
 
Reference 
1.70 
1.35 
 
 
0.000 
0.073 
 
 
1.31 - 2.20 
0.98 - 1.30  
    
Hispanic Ethnicity  1.36 0.000 1.16 - 1.58 
    
Race 
   White  
   African American/Black 
   American Indian/Alaskan Native  
   Asian/Pacific Islander  
    
 
Reference 
1.31 
  .776 
  .915 
 
 
 
0.004 
0.680 
0.610 
 
 
 
1.09 -1.58 
0.23 - 2.59 
0.65 - 1.29 
 
Vital Statistic (0=Alive; 1=Dead)    .185 0.000 0.15 - 0.23 
    
Beale Metro vs. Non Metro*    .780 0.076 0.59 - .03 
    
Distance From Breast Cancer Trials 
   Less than 45 Miles  
   >45-100 Miles 
   101-200 Miles 
   More than 200 Miles    
 
 
Reference  
2.02 
0.73 
1.49 
 
 
0.000 
0.006 
0.021 
 
 
1.65 - 2.48 
0.58 - .915 
1.06 - 2.09 
Grade of Cancer  
1=Well Differentiated 
2=Moderately Differentiated 
3=Poorly Differentiated 
4= Undifferentiated 
5= Grades 5-8 Cell Types 
6=Undetermined/Unknown  
 
Reference 
2.10 
2.11 
0.96 
5.27 
1.34 
 
 
 
0.000 
0.000 
0.884 
0.184 
0.091 
 
 
1.53 - 2.87 
1.56 - 2.85 
0.57 - 1.61 
0.45-60.95 
0.95 - 1.86 
 
_____________________________________________________________________________ 
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Table 2.5 Continued  
 
 
Notes:  Beale Metro versus Non-Metro Codes are determined on the basis of population. Metro areas are 
defined as areas with a population of 250,000 to 1 million or more; Non-Metro areas are less than 250,000 
and include small cities, suburban and rural areas. 
_____________________________________________________________________________________ 
 
 
Overall, uninsured patients, including those who self-pay, were 70% more likely 
to be diagnosed at a later stage (p-value <0.000, 95% CI 1.31, 2.20). Being of 
Hispanic/Latino ethnicity was associated with a 36% increased risk of being diagnosed 
at a regional/metastatic stage (p-value <0.000, 95% CI 1.16,1.59). Similar to prior 
research on risk factors among breast cancer patients by Ghafour et al., African 
American AYA breast cancer patients in Texas were 31% more likely to be diagnosed at 
later stages of cancer (p-value 0.004, 95% CI 1.08. 1.58) [38]. None of the other race 
categories were statistically significant in the model.   
Distance from breast cancer clinical trials was significantly associated with 
diagnosis at later stages by 102% (p-value<0.000; CI 1.65, 2.48) for those living at 
distances between 45 and 100 miles from a trial. This was not a consistent trend, since 
those patients living between 101 and 200 miles from a trial were 23% less likely to be 
diagnosed at a later stage (p-value 0.006, 95%CI .585, .916). This protective factor may 
be due to socio-economic factors or other confounding issues not captured in the 
analysis. However, those patients living furthest from a clinical trial, over 200 miles, 
were 49% more likely to be diagnosed at later summary stage (p-value 0.020, 95% CI 
1.06,2,09).    
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Grade of tumor at diagnosis was significant for those breast cancers with higher 
grades, those that were moderately or poorly differentiated. Higher grades indicate a 
tendency for tumors to grow and spread faster and have a poorer prognosis. AYAs 
diagnosed with moderately differentiated cancer cells were 110% more likely to be 
diagnosed at a later stage as compared to those with well-differentiated tumor cell 
structure (p-value <0.000, 95% CI 1.54, 2.88). Similarly, those AYA breast cancer 
patients diagnosed with poorly differentiated cells were 111% more likely to be 
diagnosed at later stages (p-value <0.000, 95% CI 1.56,2.89). None of the other grades 
analyzed in the model showed statistical significance.  
Discussion 
Our study findings are consistent with prior studies assessing the multifactorial 
nature of delayed diagnosis of breast cancer among AYA women, which may be driven 
by patient, provider, system, and environmental factors [39]. Encouraging increased 
AYA enrollment in breast cancer clinical trials and improving access to tertiary cancer 
treatment centers that offer specialized cancer care may improve outcomes among AYA 
breast cancer patients. However, a clear obstacle in Texas, and perhaps elsewhere, is the 
lack of clinical trials and the distances patients must travel to participate in trials.  
Mechanisms, such as the online matching system offered by BreastCancerTrials.org, 
currently exist to provide breast cancer patients and providers information on existing 
trials. Future research should identify more effective ways to promote utilization of these 
services among patients and especially among referring physicians.    
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This study indicated higher risk factors for Black or African American AYA 
women. Previous research indicated that White women had higher rates than Black 
women after age 40, and that the reverse was true among younger cancer patients.  This 
is known as the black-white crossover and, in our results, the Black AYAs in Texas had 
higher rates of incidence than White AYAs [38].  
Other factors that may influence the rates of AYA cancer incidence include 
higher diagnoses of familial and genetic cancers such as triple negative breast cancers 
and BRCA1/2. However, for the time period in which the data was collected (2005-
2009) the Texas cancer registry did not capture patients’ hormone receptor status, 
including triple negative breast cancer status. In 2011, the TCR began collecting 
hormone receptor status for cancer patients, including triple-negative status. However, 
they do not collect, and have no plans to add, BRCA1/2 status. The SEER databases 
began collecting this type of information in 1990. 
 This population-based study is among the first to assess risk factors for in situ 
and local diagnoses as compared to regional and metastatic summary stage diagnoses for 
AYA breast cancer patients in relation to distance to breast cancer clinical trials. The 
findings were consistent with previous studies among older women that found higher 
risk for later stage diagnosis among Black/African American and Latina/Hispanic breast 
cancer patients, as well as recent studies of AYA breast cancer patient considering 
biological factors [27].   
Future AYA breast cancer studies should be designed to include information on 
breast cancer sub-types, especially those found more frequently among young women of 
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Black/African American and Hispanic descent. Future studies should consider factors 
not covered by this study including physical activity, body weight, and co-morbidities. 
Other risk factors that might be included in future AYA studies include multi-parity, oral 
contraceptive use, smoking, lifestyle, and environmental contextual factors [39].  
 The findings in this study are subject to several limitations. One limitation is the 
lack of income and education levels of the individual patients. Both poverty and 
education have been shown to be factors in breast cancer stage at diagnosis. [40,41].  
There may be other factors that affect AYA women’s decisions to participate in clinical 
trials that were not considered in this analysis. The matching of women to the open and 
accruing early and late stage trials is a possible limitation, as each trial would have 
specific inclusion and exclusion criteria. However, this is more a limitation to the Late 
Stage trials as most of the Early Stage trials inclusion criteria are simpler and primarily 
require a histologically confirmed diagnosis of breast cancer. The trials considered in 
this study were those open and accruing in 2012-2013. It is possible that some portion of 
the trials that were considered would have been open during the later part of the study 
period (i.e., 2007-2009), as Phase III trials are often open for 5-7 years. The actual 
numbers and types of trials to which the women might have been considered for could 
have been different during the 2005 to 2009 time period. However, the diagnosis for 
early or late stage among the patients is consistent with their eligibility for participation 
in trials. During the time period that the patients in this study were diagnosed (2005-
2009) there were fewer breast cancer trials and potentially fewer trial locations open in 
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Texas. Thus, this makes the analysis of risk factors associated with trial distance 
conservative.   
In summary, our study identifies several factors that increase risk for AYA 
women to be diagnosed with breast cancer at later stages including travel distance to 
trials, insurance levels, and being of African American or Hispanic descent.  The study 
suggests opportunities for additional research considering distance and other factors that 
may influence the stage at which AYA women are diagnosed with breast cancer. These 
findings support the need for improving access to clinical trials for AYA breast cancer 
patients, for additional research on the unique physical and biological characteristics of 
young breast cancer patients, and the need for continued education of both patients and 
treating physicians, which ultimately will translate into improved AYA patient survival. 
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III.   QUALITATIVE EVALUATION OF ACCESS AYA CANCER 
SURVIVORSHIP EDUCATIONAL PROGRAMMING 
 
 
Introduction 
 
In the United States, improvements in overall cancer survival rates experienced 
by AYA cancer survivors ages 15-39, have not kept pace with survival rates for adults 
and pediatric patients [12]. AYA cancer survivors face long term risks from their cancer 
care, including excess risks of mortality, incidence of secondary primary neoplasms, 
cardiovascular disease, neuroendocrine and neurocognitive dysfunction, and 
psychosocial effects [11]. Intellectual and psychosocial concerns such as depression and 
anxiety also affect this group, as they frequently suffer developmental, cultural, and 
educational setbacks as a result of their cancer treatment [43]. Researchers speculate that 
the lack of improvement in AYA survival may be due to a combination of factors 
including lack of access to care [12].    
Albritton and Bleyer’s research suggests that there are gaps in both provider and 
survivor education to address the unique needs of AYA cancer survivors [19]. Since 
2006, with the publication of the NCI’s and LIVESTRONG Foundation’s first joint 
Progress Review Group in AYA Oncology, AYAs have received increased attention as a 
population that experiences disparities in care, including poorer survival rates overall 
than both older and younger cancer patients [11].   
Yet, today, few resources exist to train community medical professionals on the 
unique survivorship needs of AYA cancer survivors. This lack of information 
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underscores the need for integrated programs that: 1) train providers and educate 
survivors; 2) establish networks and shared models of care with transition paths from 
treatment to community care; and 3) build health promotion tools to support improved 
quality of life among AYA cancer survivors.   
The After Cancer Care Ends, Survivorship Starts for Adolescent and Young 
Adults (ACCESS AYA) patient and family educational programming was designed to 
build health literacy around AYA survivorship issues, and to stimulate improved 
communications between survivors and healthcare providers with the goal of improving 
overall quality of life and wellbeing among survivors, their families, and caregivers. The 
project was funded by the Cancer Prevention and Research Institute of Texas and 
operated by the Seton Healthcare Family, a hospital system in Central Texas. This 
evaluation effort was funded through the grant to Seton Healthcare Family to the Texas 
A&M School of Public Health. The ACCESS AYA evaluation was conducted under 
protocol IRB2013-0498D approved by the Texas A&M University Institutional Review 
Board (IRB).  
The primary aim of this paper is to share results from a mixed methods, but 
primarily qualitative, evaluation of the ACCESS AYA project based on semi-structured 
interviews from four sets of stakeholders: AYA survivors, healthcare providers including 
both nurses and physicians, hospital administrators, and leaders of cancer survivor 
advocacy groups. The paper addresses the central research question of “How did the 
ACCESS AYA program increase health literacy, communications, and understanding 
among AYA survivors and providers?” As sub-questions to this inquiry, we also focus 
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on the common barriers that AYA survivors experience and stakeholders’ perceptions of 
opportunities for sustaining and expanding AYA survivorship education programs.  
The qualitative themes and analyses of this study reflect and build upon the 
findings from the periodic and final quantitative evaluations and reports that were 
submitted to CPRIT and the Seton Healthcare Family executives. The quantitative 
assessments were important, as they reported on numbers of survivors and healthcare 
professionals served, and the types and numbers of print and digital health materials 
delivered throughout the project period [44]. This qualitative evaluation provides for 
deeper insights into what the participants valued, and provides richness in understanding 
what elements of the educational programs were most important across the spectrum of 
stakeholders. Additionally, the stakeholders’ responses to question about what barriers 
continue to affect them can help identify areas for additional communication and 
educational programming. Finally, the themes and areas of discussion for sustainability 
and future development can be used to inform future system and policy changes.  
ACCESS AYA Theoretical Framework 
The ACCESS AYA program’s educational efforts were focused on improving 
the AYA survivors’ wellbeing, and supporting changes in their behavior, as well as 
changes in healthcare professionals’ knowledge and clinical practice behaviors. We 
anticipated that the effects of the educational programming would extend into the 
broader clinical, social, cultural, and political environments of the survivors and 
providers. Based on McLeroy et al.’s social ecological framework for behavioral health, 
  44
the research team identified five levels of societal influence in order to construct a 
theoretical model (Figure 3.1) for use in our analyses of the interview narratives [45].  
Our social ecological model places the AYA survivors at the center, where 
physical characteristics, attitudes about survivorship, knowledge, and values exist in 
relationship to individual health and wellbeing. The AYA survivors’ educational node in 
the framework encompasses interpersonal relationships with clinicians, parents, partners, 
friends, and peers, including social media relationships that influence the survivors’ care 
and health behaviors both at home and in clinical settings. 
 
AYA Survivor 
Wellbeing 
AYA Survivor Educa on 
Bio/Psych/Social Skills   
Family/Peer Support   
  Social Media 
Healthcare Professional  
Educa on   
AYA Knowledge Base 
Transi on in Care  
Naviga on Services 
Cancer Advocates  
Community Support  
Research  
Resource Sharing 
 
Seton Healthcare Family 
 Community  Healthcare  
Societal Support (Poli cal, Economic, Cultural) 
 
Figure 3.1 ACCESS AYA Theoretical Framework 
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  On the right side node are the influences of the healthcare professionals’ 
education—the knowledge base of physical and psychosocial late effects that influence 
care and treatment, awareness of transitional needs, and use of survivorship navigation 
services to support and sustain survivor wellbeing. The surrounding layer of the Seton 
Healthcare Family organization and community-based healthcare represents the 
organizational norms, culture, and resources of the community healthcare environment. 
In the closer of two outer rings, the cancer advocacy groups represent a powerful 
and contributing sphere of influence in AYA cancer survivorship including physical, 
financial and social support, research efforts, resource sharing, and dissemination. The 
final outer ring indicates the levels of societal support for cancer survivor wellbeing 
including policies for insurance, financial and social support, and cultural attitudes and 
values that affect how AYA survivors are perceived and supported, or left isolated in the 
workplace, at school, and in the community.    
Each of these levels, or spheres, in the theoretical framework is laden with value 
judgments of the research team, of the interviewers, and the individuals being 
interviewed. As such, this narrative evaluation of the ACCESS AYA program is 
naturally influenced by the social context and values embedded in each group as they 
relay their perceptions of the program effects, barriers, and potential for sustainability. 
The criteria and approach for this qualitative evaluation are based in the 
constructivist models suggested by Guba and Lincoln with criteria including [45-47]: 
 Credibility (i.e., faithful descriptions or interpretations of human experiences)  
 Fittingness (i.e., how a study findings fit outside the study and if viewers will 
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find the evaluation results meaningful in their own experience)  
 Auditability (i.e., if the study is detailed in such as way that it can be replicated) 
  The importance of auditability, especially for a qualitative evaluation is 
emphasized by Sandelowski who suggested that audibility can be enhanced through 
description of the project and clear explanations and justification of 1) study rational; 2) 
articulation of the researchers’ views on the subject; 3) purposes/goals of the study; 4) 
description of participant engagement; 5) mutual influences among the researchers and 
participant/stakeholders; and 6) explicit details of data collection, analyses and 
transformation [48]. Using these criteria as guidelines and as a statement of the 
evaluators’ philosophical approach to the evaluation, the remainder of this research 
report describes the methods, data analysis, findings, and results and a discussion of 
future directions. 
Methods 
The ACCESS-AYA program was designed as a strategic combination of 
provider and survivor education directed at community healthcare providers, AYA 
survivors, their families, and cancer patient advocates. The program’s professional 
medical education was targeted at community and hospital-based family practice and 
internal medicine physicians and nurses, as suggested by Freyer, these are the 
professionals most likely to provide follow-up medical care to AYA cancer survivors 
who have transitioned from oncology care into community care [49]. There were three 
elements to the professional education: 1) formal, for-credit, accredited continuing 
medical education program (CME); 2) a half-day live educational CME session that 
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included case studies and presentations on AYA late effects; and 3) a series of medical 
briefs titled  “AYA Prompt Evidence Assessment and Review of the Literature,” known 
as “AYA-PEARLS.” Examples of the AYA-PEARLS and a list of the program’s 
professional and patient education videos and print materials are provided in Appendix 
B. 
Feelings of isolation and lack of peer support has been identified by Zebrack as 
an important issue and concern among AYA cancer survivors, both during their time in-
treatment and post-treatment [50]. To address this need, the ACCESS AYA program 
produced two annual, half-day interactive, educational sessions for survivors, friends and 
family, and community cancer advocates. During the project operating period, an 
estimated 4,000 Central Texas AYA survivors, 15,000 physicians, and 18,500 nurses 
across Texas received information about the ACCESS AYA program via mail, email, or 
print materials. As reported in the project’s final report to CPRIT, direct interpersonal 
contact was made with approximately 325 AYA cancer survivors, 785 health care 
professionals, including nurses, physicians or residents, and over 175 cancer advocates 
and care givers [44]. 
Use of mHealth social and digital media was an important element in the 
survivor public education efforts. In collaboration with the Communities of Texas 
Cancer Activity Resource Education Support (CTxCARES, a Center For Disease 
Control (CDC) Cancer Prevention and Control Research Network funded project at 
Texas A&M School of Public Health, the ACCESS AYA grant supported marketing and 
dissemination of the AYA Healthy Survivorship iPhone app. Over 850 users 
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downloaded the Healthy Survivorship app from the Apple App store during the project 
period.   
The app provides an interactive AYA survivor health and well-being assessment 
and links to the Children’s Oncology Group’s Health Links, several of which are offered 
both in English and Spanish. Both the iPhone app and its companion website 
(www.healthysurvivorship.org) offer AYA survivors links to the LIVESTRONG and 
Journey Forward cancer survivorship care plans.   
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Figure 3.2 ACCESS AYA Evaluation Sampling Frame 
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The evaluation sampling frame, shown in Figure 3.2 was designed to include 
approximately twenty participants, five from each of the following groups: 1) healthcare 
professionals (i.e., nurses and doctors); 2) hospital administrators and executives; 3) 
AYA survivors; and 4) community cancer advocates. The initial contact with the 
participants was via an email that included a survey to ascertain their willingness to 
participate, an online consent process, and information on how to contact informants 
who agreed to participate in the evaluation process. This survey also assessed 
respondents’ awareness of the ACCESS AYA programs and their perceptions about 
program effectiveness. 
In addition to the email request, a request for interested AYA survivors to 
participate in the research study with a link to the survey was posted on a Facebook page 
operated and maintained by Central Texas AYA survivors. Of the 22 informants who 
participated in the survey, 21 were willing to be interviewed, and 18 interviews were 
conducted. Table 3.1 provides information on the degree to which survey participants 
were aware of the ACCESS AYA programs and their perceived level of effectiveness of 
the program  
The team included two investigators conducting the interviews, with two 
different investigators, of which I was one, analyzing the raw data and providing the 
coding and analyses of the materials. The coding was done under the guidance of an 
experienced qualitative researcher, and all members of the team have experience in 
health behavior research in cancer survivorship. A general interview guide was 
developed and tailored with questions specifically relevant for each type of participant. 
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The semi-structured interview questions were designed with reference to Stufflebeam’s 
Context Input Process Product (CIPP) model of evaluation practice [51, 52]. The CIPP 
model considers evaluation as an essential component of improvement efforts and adapts 
well to qualitative evaluation of programs like ACCESS AYA where there is a need to 
include context, input, process, and impact statements with deep engagement of a variety 
of stakeholders. Examples of the consent documents and the full interview protocols for 
each of the stakeholder groups are provided in Appendix A. 
The interview guide questions for healthcare professionals and AYA cancer 
survivors are provided in Figures 3.3 and 3.4, respectively. From among the 21 
stakeholders who agreed to participate in interviews, 18 interviews were conducted 
(scheduling conflicts accounted for the loss of three subjects). The researchers and 
research assistants individually or jointly conducted 20- to 30-minute telephone 
interviews with study participants. The telephone interviews were recorded with the 
participant’s agreement, and each participant confirmed they had understood and agreed 
to the consent process. Once consent agreement was confirmed, the interviewers no 
longer used the participant’s names so that the recorded and transcribed interviews 
would remain anonymous to the research team coding the interviews.  
The researchers conducting the interviews were experienced health behaviour 
professionals who sought to apply an open and receptive aspect to accommodate 
positive, neutral, and negative attitudes articulated by the participants. The tape-recorded 
interviews were transcribed by an external contractor, and returned as text documents. 
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The interviews were coded by the type of participant (i.e., physicans, nurse, hospital 
executive, advocate, or AYA survivor). In cases where a participant had more than one 
role (e.g., both survivor and advocate) the interviewers asked the participant to respond 
to the questions specific to one role, to the greatest extent possible. 
 
 
Figure 3.3 Healthcare Professional Interview Guide 
 
 
Healthcare Professional Questions 
1) In what ways have Seton’s professional and patient education programs on 
Adolescent and Young Adult Cancer helped you understand the needs of these 
survivors? 
 
2) In what ways have you shared information on the AYA cancer survivor professional 
or patient education programs with your colleagues or staff? 
 
3) In what ways, if any, have information or educational materials about AYA cancer 
survivors changed the way in which you do your job?  
 
4) What barriers or challenges are you aware of regarding how AYA cancer survivors 
are cared for or treated in Central Texas? 
 
5) Has the information or education regarding AYA cancer survivors changed how you 
think about or treat other cancer survivors?   If so, can you provide some examples? 
 
6) What opportunities or challenges do you believe exist in sustaining or expanding 
programs for educating professionals about AYA cancer survivors?  
 
7) What opportunities or challenges do you believe exist in sustaining or expanding 
programs for educating AYA cancer survivors and their families/caregivers? 
 
8) Do you have any additional thoughts or information you would like to share as part of 
this evaluation of the ACCESS AYA grant?	
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Figure 3.4 AYA Survivor Interview Guide 
 
Once transcribed, the interview narratives were read and checked for accuracy by 
the first author and a research assistant prior to coding. The electronic files were loaded 
into Atlas.ti (Atlas.ti Qualitative Data Analysis v.7, Germany, 2014) for coding and 
analysis.  
 The descriptive coding and framework followed fundamental approaches of 
identifying themes, developing codebooks, and constructing models guided by the 
theoretical frameworks provided by Miles et al. and Saldaña and assessed statements 
about the merit, worth, satisfaction, and/or significance of the educational programming 
Cancer Survivor/Family Member/Caregiver Questions  
1. In what ways have Seton’s education programs on Adolescent and Young Adult 
cancer survivorship helped you as a survivor (or as a survivor’s caregiver/family 
member)?  
 
2. Have you shared any of the information or education materials, including the videos 
or the AYA iPhone app, with other AYA survivors?  What about caregivers or family 
members? Is there an anecdote or story you can share? 
 
3. In what ways, if any, has information or educational materials about AYA cancer 
survivorship helped you?  For example, learning about healthy diets or physical 
activity for AYA survivors?  
 
4. What barriers or challenges are you aware of regarding how AYA cancer survivors 
are cared for or treated in Central Texas?   
 
5. Has the information or education regarding AYA cancer survivors changed how you 
think about or treat other cancer survivors?   If so, can you provide some examples? 
 
6. What opportunities or challenges do you believe exist in sustaining or expanding 
programs for AYAs?  
 
7. Do you have any additional thoughts or information you would like to share as part of 
this evaluation of the ACCESS AYA grant?   
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for the evaluation [52, 53]. These themes were present in the interview guide questions, 
thus supporting efforts to code statements in interviews to specific themes. In the First 
Cycle coding, both Descriptive and In Vivo codes were applied. The coding process 
started with both researchers independently reading the transcripts and then discussing 
early findings. First Cycle coding themes were developed independently from the 
interview guide, and additional themes emerged during the Second Cycle coding 
process. Memos were inserted into the Atlas ti database. Data analysis for the evaluation 
was informed by an analytical approach suggested by Creswell in efforts to grasp the 
themes and essential meaning of the stakeholder’s comments [55].  
During the first and second stages of analysis, both research team members 
independently coded and met with a senior researcher to discuss findings. Any 
differences or disagreements in coding or thematic analysis were resolved through  
discussions among the research team members. The inter-rater reliability of the First 
Cycle coding was 89.3%, and 78.4% for Second Cycle coding based on kappa analyses 
using Stata 12.1 statistical analysis software (Stata Corporation, Version 12.1,2012, 
College Station, TX). Quotations from the stakeholders were further categorized based 
on coding domains associated with the evaluation’s theoretical framework.  
Results 
The ACCESS AYA evaluation results are structured using the characteristics 
provided in the theoretical framework, beginning with the analyses of the interviews 
with the AYA survivors who participated in the program. Table 3.1 provides the results 
of the initial email survey that was used to preliminarily assess the participants’ 
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perceptions of the program and also to recruit participants for the telephone surveys. 
 
 
Table 3.1 Survey of Awareness and Effectiveness of ACCESS AYA Program 
(N=22) 
_______________________________________________________________________ 
Question     Mean  Standard Error     95%Confidence Interval 
Level of awareness     3.2   0.098   3.02-3.43 
 
ACCESS AYA       4  0.132   3.72-4.27 
Program effectiveness  
Note: The response scale was 1-5, with 5 as the high score. 
 
 
Table 3.2 provides examples of the First Cycle descriptive codes and their 
relationship to the theoretical model. Focal areas for the First Cycle code reflect 
perceived participant areas of concern and need from the interview transcripts.  
 
 
Table 3.2 List of First Cycle Codes and Focal Areas 
 
Framework Region and First Cycle 
Descriptive Codes  
Focal Area  
AYA Survivor Wellbeing 
Barriers to care/lack of access to care  
Awareness of late effects 
Use of care plans 
 
Educational needs  
Personal reflection on survivorship 
Need for community/peer sharing 
 
Needs of daily living  
Costs of past care  
 
Physical concerns 
 
 
Psychosocial concerns  
 
 
 
Financial/Insurance 
concerns  
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Table 3.2 Continued 
Framework Region and First Cycle 
Descriptive Codes 
Focal Area  
AYA Survivor Education 
Need for survivor education 
AYAs use of apps/digital technology 
Use of survivorship plans 
 
Information sharing practices 
AYA self advocacy  
Lack of ability to communicate with physicans 
Use of Case managers/navigators 
 
Information  
 
 
 
Training/education 
 
 
Human Resources 
Healthcare Professional Education 
Age Appropriate Care 
Awareness of late effects  
Knowledge of AYA needs 
Knowledge of Seton AYA program  
AYA sparseness/fragmentation 
 
CME uptake and professional education 
programs  
 
Referrals and transitions in care 
Coordination with navigators 
Use of survivorship plans with patients 
 
Education/Training 
 
 
 
 
Time constraints  
 
 
 
Insurance coverage 
concerns  
 
Cancer Advocates  
Advocates role in information sharing 
Attitudes about AYA research 
Knowledge of Seton and other community 
programs 
 
Family and caregiver needs  
Use of survivorship care plans for non medical 
needs 
Information 
gathering/sharing 
 
 
 
 
Delivery of resources 
Seton Healthcare Family/Community 
Physicians 
Impact of AYA Educational Programs 
Knowledge of Seton AYA program 
Financial and Human 
Resources 
 
Sustainability 
Societal Support 
(Political/Economic/Cultural) 
AYA political advocacy 
AYA Fragmentation  
Use of survivorship care plans 
 
Resources 
Influence/Power  
Practice Change 
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The refined codes from the Second Cycle coding are shown in Table 3.3. These 
codes reflect much of the First Cycle code and include additional themes and constructs 
that emerged through code review and discussion as well as additional mining of the 
transcripts.  
 
 
Table 3.3 Evaluation Theoretical Framework and Themes 
_____________________________________________________________ 
Theoretical Framework 
Characteristics 
 Themes 
 
Survivor Wellbeing  
 
Self-Efficacy 
Social Interaction with other survivors 
Use of social media (i.e., Facebook) 
  
AYA Survivor Education  ACCESS AYA Meetings/Programs 
Information on diet/nutrition 
Awareness of AYA psychosocial needs 
Self-advocacy training 
Information on late effects of treatment 
Use of AYA Healthy Survivorship App  
Increased level of peer support  
Use of Survivorship Care plans  
 
 
Healthcare Professional Education  
Awareness of AYA cognitive issues 
 
Awareness of AYA psychosocial needs 
Awareness of AYA late effects  
Palliation/end of life care  
Survivorship Care Plans  
Navigation services for patients 
Use of PEARLS for professional education  
Practice change as a result of ACCESS AYA 
Referrals and transitions in care  
  
Cancer Advocates Role/Education  Resource sharing 
Importance of AYA Survivor Research 
Awareness of AYA unique needs  
 
 
Seton and Community Healthcare 
Resources  
 
AYA Survivorship Nurse Navigator 
AYA Group Meetings  
  
Societal Support  Political awareness 
Advocacy for AYA resources/care  
_____________________________________________________________ 
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Survivor Wellbeing  
The statements of AYA survivors relating to their own wellbeing gave evidence 
of ongoing struggles and challenges physically, emotionally, and socially. Education 
programs like ACCESS AYA address a number of the issues that affect AYA survivors. 
However, for many of these young adults, the challenges and barriers of survivorship are 
considerable.  
A young brain cancer survivor shared her frustrations about the transition from 
being in treatment to the “new normal” of survivorship and her concerns about the 
ongoing financial costs of cancer care and survivorship.  
  “What would be really helpful is to figure out financial help 
because that’s kind of one of the big things. It just costs so 
much for all the treatment…the biggest thing is trying to get 
back to normal routines because you’re used to just being 
home and dealing with your sickness.” (AYA Survivor and 
Program Participant)  
 
  For AYA survivors, the concept of wellbeing is transient and is as much mental 
and emotional as physical. They struggle with the affects of their treatment across all 
the areas of the social ecological framework, physically, intellectually, socially, and 
financially. Several of the survivor stakeholders expressed concerns about the effects of 
their treatment on their mental capacity, and worried about how that might affect their 
future employment and educational opportunities. Wellbeing among survivors was also 
expressed in changed awareness and increased empathy for those they encounter.  
 “A lot of people might not even realize how sick people 
 might be and not even look it. I think my experience has  
 made me more aware and less judgmental.”  
 (AYA Survivor, ACCESS AYA Participant) 
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When asked to address the benefits of the ACCESS AYA program, several 
survivors commented on the value of being more informed and connected to the 
community of AYA survivors. According to Schroevers et al. positive social support is 
strongly protective against the distress and depression that may affect AYA cancer 
survivors and many AYAs suffer from post-traumatic stress conditions [56].  
“I appreciated the connection point, to meet some more people…  
doctors are brilliant and all, there are things that they simply don’t 
 understand because they’ve never been through it …there’s a difference 
between science and experience.” (AYA Survivor/ACCESS AYA  
Program Participant) 
 
 AYA Survivor Education 
  The ACCESS AYA educational programming for survivors covered medical and 
clinical issues, survivor advocacy, self-efficacy, and opportunities for social engagement 
with other survivors, in real time and in virtual online space. Both patient and 
professional education programs stressed the importance of the development and use of 
Survivorship Care Plans.  
“My memory is really, really bad, so it [the care plan] helps me 
to have a lot of information to hand over to my doctors.  I have 
probably eight to twelve different medical people trying to keep 
me well and going. So, it’s hard to keep up with all that. It 
helped me along the way when I can’t remember stuff.” (AYA 
Cancer Survivor, ACCESS AYA Participant) 
 
 The ACCESS AYA Summits were half-day meetings designed to provide 
opportunities for interactions with peers, healthcare professionals, and community 
cancer advocates. The agendas included a variety of interactive elements including 
physical activity, cooking demonstrations, and physicans presentations on screening and 
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surveillance for second cancers and late effects such as cardiotoxicity.  
“… some of it has been some good practical stuff on how to deal with 
finances, emotions, the insurance, second opinions, keeping records. 
My favorite part, honestly, is that it connects you to other people, both 
experts in the medical field, and other people who have been through 
it…” (AYA Cancer Survivor/ACCESS AYA Program Participant) 
 
A consistent theme throughout the ACCESS AYA education effort was the 
importance of self-advocacy and advocacy training. The educational seminars included 
survivor-led discussions on self-advocacy in dealing with the medical community and in 
life situations, as well as engagement in social advocacy for AYA survivorship concerns.  
“I think that the benefit of a young person understanding and knowing 
that they are actually part of a larger community, they’re not alone, 
that they’re part of this community, they’re part of something bigger 
and they can make a difference, I think is incredibly powerful and can 
be helpful to their own sort mental and emotional healing.” (AYA 
Cancer Survivor/Cancer Advocate)  
 
 
The shared passion and desire to participate in social advocacy among the AYA 
survivor community is perhaps an unintended consequence of the ACCESS AYA 
educational program. Several of the AYA survivor participants stated that as a result of 
learning about national AYA advocacy organizations in the ACCESS AYA programs, 
like Critical Mass and the OMG Stupid Cancer Annual Conference, they are now 
participating in advocacy at a national level.  
Healthcare Professional Education 
Education of healthcare professionals appeared to be one of the more challenging 
aspects of the ACCESS AYA program. The initial plan of offering free online and DVD 
CME materials to physicians and nurses was deemed successful only for the nursing 
  60
professionals. Despite multiple attempts to deliver the CME to physicians, uptake was 
minimal. The innovation of creating the PEARLS, both as one-page briefs and short 
YouTube videos that included cases and evidence-based facts on AYA survivorship, 
offered improved dissemination of the professional education materials. Over 350 
PEARL packets were delivered to Central Texas physician offices and clinics.  
The PEARLS were delivered both as links from the Seton Survivor Center 
website and delivered directly to clinics and offices with brief presentations to the 
clinical staff. A qualitative assessment of the PEARLS dissemination effort is reported 
on elsewhere.  A community physician comments on the difficulty of continuing 
education and the PEARLS as a delivery mechanism:  
“So, the education probably has to come case-by-case. 
That is the way most of us learn anyway. A lot of people   
are getting a lot of education off emails, webcams 
and this kind of short vignette.” 
   (Community Physician) 
  There were differing perceptions in the value and opportunity for providing 
physician education, as is evidenced by these comments from a second community-
based physician: 
 “I think it’s a challenge, frankly, to educate any 
professional once they’ve finished their training. I just 
think that a lot of people are so busy and so overwhelmed 
with just workload that taking time for professional 
education that isn’t mandated by their specialty board, it’s 
just not going to happen.”  (Community Physician) 
 
A cancer survivor advocate, who also served on the ACCESS AYA advisory 
group, had a differing opinion regarding healthcare professional education. 
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 “I think educating professionals is a real problem in the 
young adult community.  Because the young adults patient 
population is fragmented between adult and pediatric and 
community and academic, I think anything that we can do to 
break down those walls is what we have to do to move the 
field forward and to improve the care and treatment of these 
young adult patients.” (Cancer Advocate and ACCESS 
AYA Advisory Board Member) 
 
Despite these concerns, there was dispersion of the professional training through 
the system as evidenced by resident training programs for AYA cancer survivorship 
provided by a Seton staff physician and via comments from both nurses and physicians 
about sharing the ACCESS AYA materials with staff and colleagues.  
Concerns for the complexity of care of AYA patients and comments about the 
need for better transitions of patients from cancer care to community care were themes 
in the health care professional interviews. Both physicians and nurses expressed 
concerns about lack of time for education as well as the relatively few numbers of AYA 
survivors among their practice populations.  
  An ACCESS AYA goal for physicians’ education, in addition to delivering 
information and education, was practice change. A community-based palliative care 
physician reflects on changes in her practice behavior as a result of the ACCESS AYA 
programming: 
“I’ve tried to be more deliberate about preparing patients for 
survivorship while they’re in treatment. I think systematically 
what we used to do is treat the patients, and then be a little 
befuddled as to why they weren’t feeling great afterward, 
either physically or emotionally or both.  I've started to be 
more deliberate about trying to prepare patients for when 
they finish treatment… I have gotten more tuned into the need 
for behavioral health support for patients who are not yet in 
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survivorship... the bigger questions of meaning and co-
morbid mental health problems are harder, a lot harder.” 
(Community Palliative Care Physician) 
 
According to the views of both the health care professionals and healthcare 
administrators, the ACCESS AYA program was successful in creating the content and 
materials for professional education, but struggled in dissemination and adoption. The 
delivery of the video and print PEARLS were perhaps the most successful elements of 
the program in that they delivered evidence-based information in a timely and succinct 
manner and required little investment of time from the healthcare providers.   
Community Cancer Advocate Education  
Cancer advocacy groups and advocate leaders frequently take on the role of 
bridging between the medical community and the patients and their families. Modeled 
partially on the success of breast cancer advocacy, AYA advocacy groups work to 
ensure that the unique medical, psychosocial, supportive, and educational needs of 
teenagers/adolescents and young adults living with cancer are met. The roles of 
advocacy groups include bringing individuals interested in change together, and 
providing coordinated education and support services as well as policy analysis and 
response. Much of the focus of the national AYA advocacy groups is to bring 
researchers together with survivors to support increased recognition of the unique needs 
of this population including developing specialist facilities for treatment and 
survivorship, addressing concerns for delayed diagnosis and seeking to improve access 
and quality of care. Central Texas is home to both the national headquarters of the 
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LIVESTRONG Foundation, with its strong focus on AYA survivorship, and the newly 
formed Critical Mass AYA advocacy group.   
 “I think that it is not unique to Central Texas. I think that a 
challenge that is faced everywhere is this fragmentation of the 
young adult patient population, and the difficulty in breaking 
down silos of their care and treatment and service. I find that 
so often the frustration is people don’t get me, they don’t 
understand what it’s like to be a young person with cancer. 
Why am I getting materials for old people? It’s different to be 
in my position. This gives rise to the isolation and the fact that 
you don’t have anyone, if you’re socially isolated, to process 
your experience with.”  (AYA Survivor and Cancer 
Advocate)  
 
A consistent theme among the cancer advocates was their role in the community 
in sharing and distributing educational resources and programming.  Several of the 
cancer advocates participated in the two AYA annual summits held during the project 
and used the venue to both distribute their own information and gather other resources 
for sharing with their constituencies. 
Sustaining ACCESS AYA Educational Programs  
Programs like ACCESS AYA face challenges in efforts to sustain and expand 
their reach due to competition for funding and ongoing challenges in hospital and 
healthcare operations. When asked about their thoughts regarding sustainability, most 
respondents mentioned the competition for funding. However, there are valuable insights 
regarding what it will mean to sustain survivorship education efforts in emerging areas 
such as caregiver support and palliative care both for pain management and end of life 
care.     
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“To make an analogy…we prep people for a hurricane. We take care  
of people during the hurricane, and we may provide some emergency  
services after the hurricane, but …we don’t help people rebuild when 
that hurricane is all through… I look at caregivers as a patient  
population that’s emerging and that we are ill-equipped to care for.” 
(Community Palliative Care Physician) 
 
ACCESS AYA appears to have succeeded in increasing awareness of AYA 
survivors as a unique population and building a sense of community among AYAs, their 
caregivers, and advocates. The survivors’ self-avowed increased social and political 
awareness and desires for activism is also an indicator of increased self-efficacy. These 
elements tie to the societal support realm in the evaluation’s theoretical framework 
related to building skills and support for political, economic, and cultural aspects of 
AYA survivorship. Both the cancer advocates’ and the AYA survivors’ interviews 
indicated that the participants found value and benefit in the increased sense of 
community and the potential to take action based on information and education provided 
by the ACCESS AYA program. There were also indications among the healthcare 
professionals that increased advocacy and self-management both for patients and their 
families was a positive benefit of the ACCESS AYA programming.  
Among the most powerful elements in programs like ACCESS AYA and the 
Seton Cancer Survivor Center are the creation and support for group meetings of AYA 
survivors. The online Facebook and in-person support community were primarily a 
creation of the Seton Cancer Survivor Center, but they also reflect the increased 
emphasis on survivor education and communication from the ACCESS AYA grant 
efforts. The engagement of the AYAs survivors in group meetings demonstrates the 
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development of a sustainable community engaged in sharing resources, wisdom, and 
information.    
 “I think a lot of people really identified with that because they were  
 able to hang out with people that had, I guess, maybe the same 
 limitations… or similar backgrounds to them and they felt more  
 comfortable…  
They really seemed to enjoy the fact that it wasn’t all based on  
the illness or the complications… it was based on having fun,  
being normal and moving on…” 
  (AYA Cancer Survivor/ACCESS AYA Participant) 
 
Discussion 
ACCESSS AYA was designed to address both a knowledge gap and a delivery 
gap among AYA cancer survivors and providers. The knowledge gap is the lack of 
information and awareness among AYA survivors and providers about the 
characteristics that make this population unique among cancer survivors as a group that 
experiences disparities in survival increased mortality, greater incidence of second 
cancers, and late effects of treatment and psychosocial concerns that affect quality of 
life.  The stakeholder groups in the evaluation shared perceptions that were unique to 
their experience, some reflecting on the ACCESS AYA materials, and others on AYA 
survivorship concerns in general. The delivery gap is an opportunity for increased 
information and resource sharing among healthcare professionals, both oncologists and 
community providers as well as among the survivor and advocate stakeholder 
communities. This finding is supported by Zebrak in his analysis of the service needs of 
AYA survivors [43]. Across all of the stakeholders there was general agreement on the 
importance of programs and educational efforts to ensure the wellbeing of the survivors. 
  66
Similarly there was consensus that the building of a knowledge base and community 
repository of resources to support AYAs in their survivorship efforts. AYA survivors’ 
needs regarding information sharing, especially among peers, were assessed in research 
by Freyer [48]. Among the survivors and cancer advocates there was acknowledgement 
and support for increased social support and peer engagement, which was identified as 
one of the key research gaps in a recent National Cancer Policy Forum Workshop held 
jointly by the LIVESTRONG Foundation and the IOM [57]. 
The results of the evaluation indicate that the program was perceived in a 
positive light, by the members of the representative stakeholder groups interviewed—
AYA survivors, clinical healthcare professionals, administrative healthcare 
professionals, and cancer advocates. However, some of the physicians claimed to have 
not been fully informed of the program, and others indicated that difficulty in finding 
time for educational activities given their patient load and clinic demands. Among 
cancer advocates, there were concerns about the need for additional and ongoing 
dissemination of the educational materials. Among survivors, most indicated benefits 
from both the educational program and the navigation and care plan provision services 
provided by the Seton Survivor Center.  
The survivor benefits were in the domains of increased awareness of late effects, 
use of the app and social media, and increased peer support and engagement. The AYA 
survivors also indicated increased self-efficacy both for their engagement with 
physicians and in healthcare settings and in policy advocacy for the regional and national 
AYA survivor community.  
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Among physicians, nurses, and health care administrators there was clear 
evidence of increased knowledge of AYA health and psychosocial concerns and greater 
awareness of the unique needs of the AYA population. There was evidence of practice 
change in the way nurses and physicians treated and perceived survivors’ post-treatment 
needs, both physical and psychosocial. The high level of effectiveness and value of the 
nurse navigator and staff of the Seton Survivor Center were remarked upon by both 
survivors and providers. While the nurse navigator was not directly funded by the 
CPRIT grant, her engagement in the project as an advisor and collaboration was an 
important element in the success of the education programming.  
With reference to the principles of triangulation in evaluations suggested by 
Jonson, qualitative evaluation findings are consistent with the findings of the objective 
qualitative evaluation of the ACCESS AYA program [44]. As was offered in the 
participant survey, the research team provided those participants who requested it the 
full report to review and have sought feedback and critique of the evaluation from 
project stakeholders.  
Qualitative analyses and evaluations allow us to share the voices of the 
stakeholders and participants from an interpretive perspective. In considering the 
limitations in this evaluation, the research team attempted to recognize the subjectivity 
of their lenses in viewing the ACCESS AYA project. The selection of the interview 
participants may be perceived as a limitation, as they were self-selected. The participant 
sampling frame was well reasoned, and the inclusion of groups of AYA survivors, health 
care professionals, and advocates was highly relevant to the evaluation research. The 
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views expressed by the AYA survivors may not reflect the perspectives of AYA cancer 
survivors who prefer to forget about their cancer experience, or those who are less 
affected by late effects of treatment.  
An assumption was made that data collection via phone interview was 
appropriate for the research objectives and the settings. Also, the limited time for some 
of the phone interviews was driven by the time constraints of the healthcare 
professionals. Limitations may exist in the narrow use of interviews as the primary 
source of data. However, the research team was familiar with the print and video 
materials of ACCESS AYA, and team members participated in field observations, 
providing additional richness and robustness to the evaluation analysis. Finally, the 
results and data must be appropriately analyzed and the findings adequately corroborated 
by using multiple sources of information. Qualitative studies such as this evaluation have 
the potential to complement the quantitative evaluations by bringing to the forefront the 
multiple realities of the various stakeholders. The values and benefits of the program 
evaluated reflect the realities of the lives and work of the participants.  What worked in 
ACCESS AYA, and what challenges and opportunities remain, are articulated through 
the voices of those most affected.   
In responding to the evaluation’s primary and secondary research questions 
regarding the value and benefits of both AYA survivor and professional education, we 
suggest that overall, ACCESS AYA was moderately successful in reaching its intended 
population, but that additional work is needed to continue the educational efforts. 
  69
The evaluation and the ACCESS AYA program were built on an action agenda 
for change, through education and information, in the way that AYA survivors perceive 
themselves and are perceived by their peers, providers, advocates, and communities. The 
agenda for change includes ongoing developments in the skills and knowledge base of 
community healthcare professionals, doctors, nurses, and administrators who treat and 
care for AYA cancer survivors.    
This evaluation offers a substantive contribution to the understanding of the 
AYA survivor community and to the healthcare professionals and advocates that aid 
them in their efforts to a new “normal” life and wellbeing in their survivorship. This 
evaluation highlights the need to continue to build the survivor and professional 
resources to address the unique impact of cancer on the quality of life and wellbeing of 
AYA cancer survivors. To adequately provide quality care for AYA survivors, health 
care organizations and providers must address both the health and the psychosocial 
needs of this population. To do so will require ongoing research in the understanding 
AYA survivors as a highly heterogeneous population that requires management of 
cancer and treatment late effects including fertility, body image, and cognitive and most 
particularly psychosocial effects and care needs. As part of this process, policy and 
programmatic improvements are needed to facilitate transition to AYA survivors into 
community and off treatment care through the provision of care plans and age 
appropriate information and support service resources.   
The development of survivorship research methods and measurable outcomes to 
support evidence-based educational materials and guidelines depends on the availability 
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of funding opportunities at a time of increasingly limited resources and economic 
pressures in both academic and healthcare settings. The ability to develop quality 
research studies related to the AYA population is also dependent on the recruitment of 
sufficient numbers of survivors into these studies. It is hoped that through ongoing 
efforts to engage survivors, providers and advocates in programs like ACCESS AYA 
can also extend into community-based participatory research efforts.   
An additional cost effective opportunity for engaging AYA survivors in 
evaluation and survivorship quality of life research is through the use of mobile based 
applications and technologies, as is demonstrated in the use and adoption of the AYA 
Healthy Survivorship app. Mobile technologies are emerging as effective tools for 
survivorship engagement and care as well as tools for provider and survivor education.  
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IV. APPS SEEKING THEORIES: MOBILE APPLICATIONS AND HEALTH 
BEHAVIOR CHANGE INTERVENTIONS 
 
Introduction 
"We tend to overestimate the effect of a technology in the short run and underestimate 
the effect in the long run." - Roy Amara, leader at the Institute for the Future 
 
With the advent of smartphones and texting, the use of mobile phones has shifted 
from a voice device to an Internet accessible hand held compute. In this shift, the large 
market of mobile software applications has emerged. As of May 2014, the United States 
had 345.2 million mobile subscribers [59]. This is more than one mobile subscription per 
person, based on the U.S. World Bank population estimates of 313.9 million [60]. 
According the Pew Internet and American Life Surveys, 91% of U.S. adults own a cell 
phone and 60% use their phone to access the Internet [61]. 
Mobile technology, cell phones, smartphones, and tablets provide any time 
anywhere access to health information, health promotion, and behavioral interventions.   
Use of mobile technology for health seeking information is high, with 31% of 
smartphone owners using their mobile phones for health information [61]. Mobile health 
(mHealth) is defined as: “using wireless mobile communication technology to aid health 
services delivery” [60]. One of the promises of mHealth is that it can empower 
individuals to be active in their own care through tools that facilitate assessments, 
monitoring, communication, and self-management. Personal mobile applications (apps) 
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are a critical component of mHealth, providing educational resources, decision-making 
tools, psychosocial communication, and social support.  
For the growing population of cancer survivors, many of whom experience 
differing needs in terms of medical care, psychosocial support, and practical needs of 
daily living, mHealth apps have the potential to provide access to information and health 
behavior interventions that are low cost, easy to access and personalized to their specific 
needs.  Increasingly, socially disadvantaged populations, including racial/ethnic 
minorities, those with lower incomes, and the elderly use smartphones as their primary 
or only connection to the Internet [60,62]. Mobile interventions oriented to cancer care 
and survivorship, education, and social engagement have the potential to inexpensively 
support cancer survivors with tools to better understand and manage their cancer care, 
both during and after treatment. While sparse, studies such as those by Bender et al. that 
address the use of mobile app interventions in cancer are beginning to explore the 
efficacy and potential of apps [63]. For the most part existing cancer smartphone and app 
research articles are disease or symptom specific. Examples include a review of pain 
management apps in 2011, by Rosser, and an assessment of colon cancer apps by 
O’Neill and Brady in 2012 [64,65].  
An emerging question concerning mHealth apps for health promotion and 
disease prevention is: “to what extent are apps based in behavior and health 
communication theories and frameworks?”  With specific relation to disease specific 
apps, previous reviews have coded cancer apps to examine which apps were 
“scientifically/clinically based” or “evidence-based” or on the basis of the app’s purpose 
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and content such as awareness, cancer treatment information, fundraising, or early 
detection [61, 64, 66].    
A systematic review of mHealth research studies by Free et al. to quantify the 
effectiveness of mHealth interventions on health behavior change and disease 
management was largely inconclusive [67]. Free and colleagues found only two mHealth 
text message interventions that demonstrated effectiveness: one for antiretroviral 
medication adherence in low-income settings, and a second for increase in smoking 
cessation in high-income settings. They suggest the need for additional research to 
understand the impact of mobile health behavior change and disease management, 
including exploring interventions that utilize multiple behavior change techniques.  
Riley and colleagues provided an overview of mobile non-cancer specific health 
apps that raised questions about the capability of current health behavior theories to 
measure mHealth effectiveness [68]. According to Riley et al., while mobile apps are 
evolving as a delivery system for health behavior interventions, few mHealth apps are 
grounded in health behavior theories. Additionally, Riley et al. suggest that current 
theories may not be “up to the task,” especially with regard to “within person changes” 
and the potential impact of dynamic feedback loops present in app operations [68].  
To date, none of the research on mHealth cancer apps has systematically assessed 
the extent to which cancer survivorship apps, as health behavioral interventions, are 
theory-based. A sophisticated taxonomy of health behavior theories and behavior change 
frameworks developed by Abraham and Michie was later refined as a system to code 
Internet interventions associated with health behavior by Webb and colleagues [23, 69].   
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Our review further adapts that taxonomy to mHealth interventions for cancer 
survivorship and seeks to investigate if, and how, behavior change theories are being 
used to inform mHealth apps for cancer survivors. By doing so, we begin to answer 
important theoretical and applied questions: What theories should app designers and 
developers draw upon in developing mHealth cancer survivorship interventions? What 
behavior techniques may be effective when delivered by mHealth apps?   
Methods 
In November 2013, we conducted a computerized search for mHealth cancer 
survivorship apps on the Apple App Store, for iPhone® and iPad® apps and on Google 
Play™ for Android™ apps.  We explored other mobile app markets including those for 
Nokia and Blackberry smartphones, but found no cancer apps, so we limited our search 
to the two major app markets. We used the following definitions and search criteria: 
1) Native apps: Native apps were considered as software applications that must be 
installed on a device such as a smartphone, iPad, or tablet and could be available 
either for the iOS or Android platform or both. Apps could have elements or 
portions of the application that are linked to websites or cloud-based servers, 
including assessments, videos, pdfs, or other linked materials but the user 
interface must be initiated on the smartphone or tablet. 
2) Cancer survivor: Any person who has been diagnosed with cancer from the time 
of diagnosis through the balance of life.  
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3) Mobile app searches were conducted on Google Plus and the Apple App Store 
using the search terms: cancer + survivor; cancer + survivorship; cancer + care; 
cancer + treatment; and cancer + management. 
4) Web-based searches for mobile apps were also made on Google, Bing, and 
Yahoo, as these are among the top search engines used in English. Search terms 
included: “cancer + mobile web”; “cancer survivorship” + mobile web; and 
“cancer survivorship app.” 
The inclusion criteria for the cancer survivorship apps include the following:  
1. Information on cancer survivorship: To be included apps had to make specific 
mention of cancer care, treatment, survivorship, or cancer survivors in the 
description found on the app store, in the website listing, or in the “table of 
contents” of the app or its navigation terms/icons.  
2. Not just a badge or skin: We excluded a large number of applications that were 
images to be used as mobile phone screen skins and did not have any interaction 
or content beyond an image.  
3. Not a fundraising application: Apps had to provide some functionality for cancer 
survivorship education, information, or health behavior change.  
4. Not just a glossary of terms or mobile version of a periodical or website. The 
application was required to offer some level of interaction for health behavior 
change beyond just a dictionary or the ability to read a publication in a mobile 
format. 
  76
5. Applicable to one or more cancer types or cancer care: Apps were considered if 
they included functionality and services for all cancers, if they provided 
information for one or more types of cancers, or if they specifically addressed 
cancer survivorship late effects as a condition. 
6. Designed for patients/survivors: Apps were included if they were designed for 
caregivers and healthcare providers in addition to cancer survivors. Apps 
designed solely for use by providers were excluded.  
7. Apps had to be available for public download and use, and not used solely for  
research studies.  
8. Apps had to be relevant to cancer survivors beyond information specific to a 
unique or individual cancer center. Branding of a cancer center in an app was 
considered allowable, but the app had to be useful to cancer survivors other than 
those served by the institution or cancer center. 
9. Only free apps were considered for inclusion, as there were no low cost (i.e., $.99 
to $1.99) available for cancer survivorship. (Note: The paid apps in the cancer 
survivorship category cost from $5.99 to $19.99.)  
The taxonomy for behavior change techniques used in this research study was 
derived from Mitchie et al.’s taxonomy of 26 health behavior change techniques with a 
few important changes based on the characteristics of mHealth apps [23]. The mHealth 
app taxonomy was limited to 15 health behavior change techniques (HBCT) with each 
described by one or more health behavior or communication theories. An additional area 
of HBCTs included in the mHealth taxonomy, but not found in Webb and Michie’s 
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taxonomy is Tailored Health Communications (THC) [70]. As indicated by Rimmer and 
Kreuter, THCs are important elements of health communications and persuasion and 
may promote action through increased motivation to process information as suggested 
by Petty and Cacioppo’s 1986 Elaboration Likelihood Model (ELM) [71]. 
The theoretical models and frameworks initially used by Webb and Mitchie that 
were included the in mHealth survivorship app taxonomy are as follows [70]:  Social 
Cognitive Theory (SCogT) (Bandura), Information-Motivation-Behavioral Skills Model 
(IMB) (Fisher and Fisher), Control Theory (CT) (Carver and Scheier), and Operant 
Conditioning (OC) (Skinner).  Also used are theories related to the impact of social 
support (SS) on health behaviors (Cohen) and social comparison (SC) (Festinger) [70-
75]. 
A coding manual was developed specifically for use in coding the mHealth apps 
for cancer survivorship (Appendix B) based on Abraham and Michie’s work, A 
Taxonomy of Behavior Change Techniques Use in Interventions: The Coding Manual  
[23].  A coding guide (Table 4.1) drawn from the mHealth cancer survivorship 
taxonomy of HBCTs and theories developed, analyzed and tested by the coders (DVD, 
KF, JP). The team tested and trained with the coding guide using three apps that existed 
both on iOS and Android mobile platforms. Master lists of identified iOS and Android 
apps were developed collectively by the coders for use in downloading the apps to their 
smartphones and tablets.  
Two coders each were assigned to each type of app platform (i.e., iOS and 
Android platform) and each coder independently loaded the apps that met the eligibility 
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criteria onto one or more mobile devices (i.e., smartphone or tablet). The coding rubric 
for the HBCT change techniques used a score of 1 to indicate that the HBCT was 
present, and a score of 0 to indicate that the HBCT was absent. Based on two raters for 
each app, total possible scores for each platform are 72 for iOS apps, and 64 for the 
Android apps. Several apps were not working and could not be loaded and a few crashed 
consistently, thus preventing coding. The only major difference in coding approach was 
related to coding of games, and that issue was easily resolved by consensus.  
 
Table 4.1.  mHealth Cancer Survivorship Taxonomy for Coding 
_____________________________________________________________________________________ 
 Behavior Change Techniques               Theory Basis   Definition  
_________________________________________________________________________________ 
1. Personalized THC/SCogT, 
ELM 
Rimer & Kreuter, 2006 define 
personalization and tailoring as a process 
for creating individualized 
communications by gathering and 
assessing personal data, (i.e., logging in 
with personal information 
 
2. Tailoring (macro/meso/micro) 
 
THC, ELM  
 
Macro occurs at the group level; meso is 
determined by individual needs of user, 
but not highly specific; micro is very 
specific to the user 
   
3. Health Behavior Linkage  IMB General information about linkage of 
individual behavior and health (e.g., 
benefits of good nutrition and physical 
activity) 
 
4. Action/Behavior Consequences 
 
TRA, TRB 
SCogT, IMB 
 
Information about potential benefits and 
costs of action or inaction in relation to 
health and wellbeing (e.g., stop smoking)  
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Table 4.1. Continued 
___________________________________________________________________________________ 
 Behavior Change Techniques               Theory Basis   Definition  
________________________________________________________________________________ 
 
 
5. Intention formation  
 
 
TRA TBP 
SCogT, IMB 
 
 
Encouraging the person to take an action 
or decide on a goal to improve treatment 
response or survivorship. 
 
 
   
6. Provide instruction  SCogT Show or tell the user how to perform a 
behavior (e.g., asking your doctor 
questions). 
 
7. Provide Materials for Education SCogT Provide information or educational 
materials about cancer care and 
survivorship 
8. Goal Setting  CT Prompting specific goal setting (e.g., walk 
5 miles daily)  
9. Self Efficacy  SCogT Aids user in recognizing skills or 
education developed  
10. Feedback on Performance CT Scores, tests, game results 
 
11/12. Persuasion (general/targeted) OC Messages to strengthen self-
efficacy/control beliefs 
 
13. Social Influence: information on peer 
behavior (passive) 
 
SCogT 
 
Facilitate users access to information on 
how others have changed behavior or 
addressed challenges (non expert) 
 
14. Opportunity for social comparison 
(active) 
 
SS/SC 
 
Facilitates active user engagement in 
social media for sharing and comparison 
 
15. Mobilize Social Norms (exposure to 
important other 
SS/SC Provides user exposure to expert 
opinions and information  
 
 
Note: OC= Operant Conditioning CT= Control Theory; Elaboration Likelihood Model; THC=Tailored Health 
Communication Model; IMB=information motivation behavioral skills model; TRA= Theory of Reasoned 
Action; TBP= Theory of Planned Behavior; SCogT= Social Cognitive Theory; SS= Social Support; 
SC=Social Comparison.  
 
Results 
The search of the mHealth cancer survivorship apps yielded a total of 97 
potentially relevant apps that appeared to meet the selection criteria.  A flow diagram 
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showing the numbers, source, and refinement of the apps identified for coding is shown 
in Figure 4.1.  
  
 
 
There were three apps that were available on both the Apple App Store and 
Google Play, and both teams coded these apps. Seven of the Android cancer apps were 
configured as games, as were four iOS games. A total of 68 apps were coded and 65 of 
these were unique. The inter-rater reliability for the iOS apps was 86.1% (p<0.000) and 
for the Android apps it was, 77.4% (p<0.000) was absent. Table 4.2 shows the results of 
the teams’ scoring of the HBCT for both Android and iOS platforms.   
iOS Apps 
N=63 
 
Android 
Apps  
N=37 
 
iOS Apps 
Rejected for failing to 
meet criteria or crashing  
N=27 
 
Android Apps 
coded  
N=32 
 
OS Apps 
Coded  
N= 36 
 
Duplicate (iOS & 
Android 
N=3 
Total number of 
Apps=97 
 
 
Games N=4 
 
 
 
 
Games N=7 
 
 
 
Android Apps 
Rejected for failing to 
meet criteria or crashing  
N=5 
 
Figure 4.1 Android and iOS Selection Flow Diagram 
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Table 4.2.  Rating Totals for Health Behavior Change Techniques 
 
_____________________________________________________________________________________ 
Technique/Characteristic                   iOS HBCT Scores (N=36)       Android HBCT Scores (N= 32)  
_____________________________________________________________________________________          
   
Personalization 48 24 
Tailoring    
- macro-tailoring  45 15 
- meso-tailoring   8   6 
- micro- tailoring 11   4 
   
Health Behavior Linkage 32 32 
   
Action/Behavior Consequences 21   2 
Prompt for Intention Formation  48 10 
   
Provide Instruction  54 10 
Materials for Education 28 12 
Prompt for Specific Goals 10 14 
Review of Goal Activity   2   2 
Self-Monitoring of Goals 24 13 
Feedback/Evaluation of Goals 18 16 
   
General Persuasion 25   2 
Tailored Persuasion 10   0 
   
Social Influence (passive) 17   0 
Social Influence (active) 18   8 
Social Norms -Opportunity for Comparison 
to Important Others 
  8   1 
_____________________________________________________________________________________ 
Note: Each item was scored as 1=present; 0=not present.  Total possible scores for each platform are 72 
for iOS apps and 64 for Android apps. 
 
 
The iOS cancer survivorship apps received higher scores across nearly all of the 
HBCT areas.  Additionally, the iOS apps appeared to have greater functionality and 
appeared to include more of the HBCTs overall, per app, than the Android apps.  The 
percentage of HBCT’s for each category of both the iOS and the Android platforms is 
shown in Table 4.3 and discussed in the following section. 
 
 
 
 
  82
Table 4.3 Category and Platform Percentages for Health Behavior Characteristics  
___________________________________________________________________ 
Technique/Characteristic                                 iOS Platform    Android Platform  
  (N=36)                               (N= 32)           
 
Personalization  67% 38%
Tailoring  
‐ macro‐tailoring   63% 23%
‐ meso‐tailoring  11%  9%
‐ micro‐ tailoring  15%  6%
 
Health Behavior Linkage  44% 50%
 
Action/Behavior Consequences  29%  3%
Prompt for Intention Formation   67% 16%
 
Provide Instruction   75% 16%
Materials for Education  39% 19%
Prompt for Specific Goals  14% 22%
Review of Goal Activity   3%   3%
Self‐Monitoring of Goals  33% 20%
Feedback/Evaluation of Goals  25% 25%
 
General Persuasion  35%  3%
Tailored Persuasion  14%  0
 
Social Influence (passive)  24%  0
Social Influence (active)  25%  13%
Social Norms ‐Opportunity for Comparison 
to Important Others 
11%    2%
______________________________________________________________________________________ 
Note: Each item was scored as 1=present; 0=not present.  Total possible scores for each platform are 72 
for iOS apps and 64 for Android apps. 
  
 
Personalization in the apps includes requiring that the user login with a user 
name and password. For most of the apps, personalization enabled access to selected 
parts of the app, and also allowed data to be entered and maintained on the app’s server 
rather than being stored onto the phone, thus providing adequate security for sensitive 
health information. Several apps requested specific information about the user’s type of 
cancer and then provided meso-or micro-level tailoring regarding concerns such as types 
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of treatment and late effects.  An example of personalization (Figure 4.2), with both 
macro and meso or mid-level tailoring is found in the My PearlPoint app developed by 
The Minnie Pearl Foundation. The app allows the user to identify what side effects they 
may be experiencing (e.g., fatigue, dry mouth, nausea). Once the user selects a side 
effect, the app provides education, health behavior linkages, and may also suggest 
specific goals or actions to reduce the identified side effect.  
Scoring on health behavior linkages was indicative of the app providing basic 
information about cancer care and survivorship, including diagnosis and treatment,  
and/or availability of resources for clinical or non-clinical purposes. Based on the high 
scores for this HBCT, on both iOS and Android apps, it appears that most of the apps, 
94% (64/68), provide a basic level of health behavior information.  
 The HBCT for “Prompt for Intention Formation” was coded as positive if the 
application included suggestions for general behavior or for formulating desired 
outcomes of a behavior for healthy survivorship (e.g., maintain a healthy  
weight, exercise daily, stop smoking, consider mediation). This HBCT concerns the 
user’s intent to do something and is different from taking the step to set a goal or initiate 
an action. An example of prompting for intent formation can be found in the AYA 
Healthy Survivorship app, an iOS app, shown in Figure 4.3.  
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An example instruction is found in detailed instructions on how to measure a 
survivor’s arm to set a baseline and do ongoing measurements to track lymphedema 
on the iOS app, Lymphedema Tracker, shown in Figure 4.4.  Following the trend, a 
greater percentage of the iOS apps (75% or 54/72) provided instruction on HBCT as 
compared to the Android apps (16% or 10/64). 
 
 
 
 
Figure 4.3   AYA Healthy 
Survivorship App: Intention 
Formation 
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A significantly greater percentage of the iOS apps demonstrated this HBCT, 67% 
(48/72), as compared to 16%, (10/64) of the Android platform apps.  To be coded as 
positive for the HBCT item for instruction, the material on the app had to be directly 
related to showing or telling the user ways to facilitate a specific health behavior change. 
An example of education specific to managing fatigue, a common concern for survivors 
and in post treatment, is found in the iOS app, My Cancer Manager from the Cancer 
Support Community (Figure 4.5). The app educates the patient on the activity of tracking 
his/her fatigue and also instructs them to consider sharing information with a provider if 
the score stays persistently high. Overall the app scores for this HBCT were low with 
39% (28/72) for the iOS apps and 19% (12/64) for the Android apps. 
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The presence of activities or information across both iOS and Android platform 
apps for goal-setting activities (e.g., prompts for specific goals, review of goals, self 
monitoring of goals, and feedback or evaluation of goals) was low overall. An example 
in the area of self-monitoring of goals were suggestions found in several apps for the 
survivor to record brief notes or keep a diary or journal to record behaviors and actions 
related to health behaviors. Examples found among the apps included journals or 
tracking tools for pain and distress monitoring, as well as suggestions for practicing 
meditation. 
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Among the iOS apps, these categories ranged from a low of 3% (2/72) for 
reviews of goal activity to a high of 33% (24/72) for self-monitoring of goals. Similarly, 
but lower still, the Android apps ranged from a low of 3% (2/64) to a high of 25% 
(16/64]). These low scores included activities in the mHealth cancer survivor game 
applications for engaging in a first-person-shooter cancer destroying activity with goals 
for hitting targets. The user generally received feedback on scores for numbers of strikes 
or targets acquired. Other apps prompted goal setting via use of guided imagery 
suggesting that the user focus energy and concentration on specific body parts or 
processes affected by cancer.  
  
Figure 4.6 AYA Survivorship 
Tip of the Day 
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The delivery of personalized or tailored messages designed to strengthen 
efficacy/control beliefs related to the initiation or execution of health behavior change 
has been heralded as an area of promise for mHealth apps. The use of mHealth 
persuasion in cancer survivorship apps includes activities or signaling for new beliefs 
and or new information. Scores in this area were low for both general and targeted  
persuasion. An example (Figure 4.6) of general persuasion can be found in the AYA 
Healthy Survivorship iOS app that allows the user to elect to receive a “health tip of the 
day.” The highest scores were found among the iOS apps, with a low for targeted 
persuasion of 14% (10/72) and a high of 35% (25/72). Persuasion barely registered as an 
HBCT area on the Android apps with a low of zero for tailored persuasion and 3% 
(2/64) for general persuasion. 
Social influence is an area of HBCT techniques that would appear to be a strong 
opportunity area for mHealth apps in cancer survivorship, given the easy access to 
mobile communities including Twitter, Facebook, YouTube, and numerous other cancer 
related blog and social networking sites. The presence of passive social influence, where 
the app provides stories, anecdotes, interviews, or case histories about what other cancer 
survivors have done or experienced in relation to THBC was again, unexpectedly low.  
For the iOS apps, only 24% (17/72) offered access to such stories and Android apps had 
no scores for this HBCT.  Active social influence, wherein a survivor might be invited to 
participate in a group or peer discussion and relay activities about their own also was 
relatively low with a score of 25% (18/72) for iOS and 0 for the Android apps.   
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The apps were examined for examples of “mobilization of social norms” in 
which the user would be exposed to the social norms of important others in relation to a 
healthy survivorship activity or health behavior change. Important others could be 
valued and trusted experts such as a healthcare professional, or a celebrity cancer 
survivor advocate. One of the apps that uses this HBCT most effectively is the 
Cancer.net app, which was developed by the American Society of Clinical Oncologists 
(ASCO) and is offered on both the iOS and Android platforms. Cancer.net provides the 
user with links for brief videos of well-respected cancer researchers and clinicians on a 
range of topics, including HBCTs. While this is an area of HBCT that offers easy access 
on mHealth apps, few of the apps reviewed in the study incorporated this potentially 
important element.  Scores for these apps were 11% (8/72) for iOS apps, and 2% (1/64) 
for the Android apps. 
The evidence base for considering highly interactive mobile games and 
interactive game-like elements for guided imagery in apps is very limited.   
The potential applications of health behavior change theories in the design of game and 
game-like interventions are significant, ranging from elements of personalization and 
tailoring for scoring to goal setting, tracking and feedback, and potentially powerful 
elements of social interaction among game participants. 
Our team was initially optimistic about the inclusion and rating of the four iOS 
and Android mHealth games and interactive apps for cancer survivorship through the 
selection criteria. App names such as Cancer Fighter, Whip Cancer, and Play to Cure 
promised much, but delivered little, as HBCT interventions. Few of the interactive or 
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game apps provided even basic education or information for HBCT. Rather, the user was 
launched into series of images and audio effects with opportunities to score by shooting 
down images on the mobile screen, but offered little or no explanation why or how they 
might be of benefit to the cancer survivor. An exception was found in Re-Mission2: 
Nanobot’s Revenge a project of HopeLabs (Figure 4.7) which initiates the “shooter 
game” by explaining that the user is the Nanobot and the goal is to “fire targeted 
treatment at growing cancer and prevent it from escaping into the blood stream.”   
Discussion 
A primary aim of this study was to analyze the linkage of HBCT interventions in 
cancer survivorship mHealth apps to theories and models that are used to predict health 
behavior change and communications. The mHealth apps in this study varied greatly in 
how they ranked in the use of theoretical elements of health behavior change. This 
study’s findings and results are consistent with prior research that asserts that mHealth 
interventions could benefit from increased use of behaviour and communications 
theories in their design [64, 65, 67, 76]. In reviewing the HBCT scores for the apps, 
three theories/models appeared to be more influential: social cognitive theory (SCogT), 
tailored health communication model (THC), and control theory (CT). However, with no 
explicit discussion regarding the design or development of the apps reviewed in this 
study, it is not clear if these theories were intentionally applied or that the design 
deliberately reflected a theoretical approach. The coders disclosed that their perception 
of weakest area for health behavior linkages, meaning that they considered HBCT as 
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present, but just barely, was among the game apps which made up 16% (11/68) of all 
coded apps.  
The mHealth cancer survivorship apps that appeared to be firmly based in HBCT 
theory were similar in that they offered multiple types of HBCTs, required 
personalization and some degree of tailoring, were highly interactive, included some 
type of questions or assessments, suggested goals and actions, and provided social 
engagement and the mobilization of social norms. Most of these examples were either 
developed by cancer advocacy groups, clinical associations, or academic researchers, 
which suggest that the information provided was more likely to be based in evidence and 
clinical research and health behavior theory. Examples include: 1) LIVESTRONG 
Cancer Guide and Tracker app, available only for iPad; 2) Cancer.net, developed by the 
American College of Surgical Oncologists, which is available on iOS and Android 
platforms and also offers a web-based version and one that is translated into Spanish; 3) 
AYA Healthy Survivorship, an iOS app developed for Adolescent and Young Adult 
(AYA) survivors developed by Texas A&M School of Public Health with late effects 
guidelines provided by the Children’s Oncology Group, and 4) My Cancer Manager  
developed by the Cancer Support Community and available only as an iOS app.    
An area of HBCT that demonstrated weak results in the coding of the mHealth 
apps considered in this study, but one that bears additional research consideration is the 
theoretical realm of social influence and social media. Cancer survivors are strongly 
influenced by their social ties and connections with others and social networks can have 
important effects on survivor health and wellbeing [78,79]. 
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Clearly, the taxonomy provided in this research for mHealth cancer apps is not 
exhaustive, and additional theories and models across different behavioral change 
techniques should be defined.  As the more highly rated apps in our study offered 
multiple HBCT techniques, it may be beneficial to design a study that takes into the 
account the interaction across multiple HBCT aspects. It may also be helpful to explore 
the differences in use, HBCT efficacy, and persistence on the device for single purpose 
apps for specific survivorship concerns in comparison to apps that offer multiple types of 
HBCT elements.  mHealth is developing rapidly with tools and technologies that offer 
significant opportunities for improved clinician and patient engagement, for self-
management and monitoring and deeper interactions with highly interactive social 
networks using text, photographs, and video to communicate. Additionally, research 
exploration into the theories and models relevant to interactive apps, mobile games, and 
the use of sensors in mHealth is timely and needed. 
An article by Tomlinson et al. further articulates concerns about both the lack of 
evidence and theory in mHealth, and how theory when it is referenced, is actually 
applied. Tomlinson’s article addresses use of mHealth primarily in lesser developed and 
under resourced counties, but raises concerns about level of evidence and 
generalizability of mHealth applications [80]. A World Bank report by Kay and 
associates that tracked over 500 mHealth pilot studies, reported that very little is known 
about likely uptake, best strategies for engagement, efficacy, or effectiveness of these 
initiatives [81]. Kay and colleagues’ review of mHealth interventions suggest that the 
apps they reviewed lacked both theoretical foundations and evidence sufficient to 
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support an evidence-based scale up. The most recent systematic review on mHealth for 
health behavior change by Free et al. was not able to identify the theoretical basis for the 
research studies reviewed [67]. Both reviews confirm that there is mixed evidence for 
the effectiveness of health intervention delivery to health-care consumers using mobile 
technologies. Moreover, both reviews’ conclusions highlighted the need for additional 
high-quality controlled trials of this mHealth application.  
These findings, regarding the potential for use of theory, supports a call for 
mHealth intervention designers to reflect more deeply and extensively on the application 
of theoretical models and frameworks in the design and development of mobile HBCT 
applications.   
The strength of this study is based in its reliance on the prior work of Abraham 
and Michie in defining the taxonomy and coding of behavior change techniques used in 
interventions and their basis in theory [32]. This research on mHealth cancer 
survivorship apps had certain limitations. The initial search and selection of cancer 
survivorship apps was restricted to the commercial descriptions of apps in the Apple 
App Store and Google Plus. As a result, we may have overlooked or missed apps. The 
search results were dependent on the terms included in the search strategy and the search 
functionality of the search engines used as well as the search engines found on the online 
stores.  We attempted to overcome the search limitation by choosing common terms and 
combinations of terms, including those we found in literature reviews of cancer care and 
cancer survivorship. We considered only apps that were in English and also excluded 
paid apps. Our rationale for selecting free apps was that we wanted to ensure that under-
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resourced survivors would likely consider the apps selected. Moreover, we only 
considered apps that were focused on cancer, and included the word cancer in the title or 
the description. It is possible that we missed apps that include cancer care and 
survivorship in addition to other chronic diseases. 
The study provides a framework for future research and contributes to the 
emerging science of mHealth interventions for behavior change. The findings 
suggest a strong rationale for investing the time and diligence into more rigorous theory-
based mHealth interventions that may incorporate, as did the apps reviewed, multiple 
levels and types of health behavior change strategies and techniques. Similarly, our 
results reinforce the need for carefully constructed studies to measure the effect and 
impact of mHealth interventions 
This research study provides insights into the use of theoretical frameworks and 
models associated with mHealth. Our findings contribute to behavioral health literature 
and to health policy initiatives by demonstrating the mHealth intervention design needs 
stronger theoretical and evidence-based underpinning. The field of research on mHealth 
interventions for behavior change is a rapidly shifting landscape with new technologies 
and systems for sensors, big data analytics, and opportunities for more patient-centric 
health care. If mHealth interventions for cancer survivors and others with chronic health 
conditions are to be successful, they will need to demonstrate that they are guided by 
theory and designed to deliver value and effectiveness. The informed use of theory in 
app development and application and translation of health behavior research on of what 
kinds of apps and HBCT actually provide lasting change and benefits to users appears to 
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be lagging behind release of new mHealth technologies. The integration of apps with 
mobile hardware, including sensors and electronic medical records, is rapidly emerging 
as evidenced by the ongoing announcements of new mhealth hardware and software. 
While the promise of inter-operability of apps, sensors and clinic data will soon be a 
reality, what is missing is the understanding of how this will translate into benefits to 
users with chronic medical conditions like cancer survivors. What is also missing is how, 
where and when will the clinicians access and use this data to educate, inform and offer 
improved opportunities for health and wellness to their patients.   
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V. SUMMARY AND CONCLUSIONS 
 
AYA cancer survivors and their community healthcare providers continue to face 
significant disparities in access to care, in transitions from treatment to community care, 
and in how to prevent and monitor for late effects of treatment. Across my three studies 
we found continued evidence of the gaps and challenges that were identified by early 
researchers, including heterogeneity of the AYA population, a lack of best practices in 
institutional delivery of care models, limited access to clinical trials, and a need for more 
astute fostering of transitions into survivorship care. As in both prior and more recent 
studies, I found that differences among ethnic, racial, and socio-economic groups appear 
to influence outcomes.   
The population-based study of Texas’ AYA breast cancer patients is the first to 
assess demographic and diagnostic risk factors associated with late versus earlier stages 
of cancer diagnosis. My findings are consistent with prior studies that found higher risk 
of later stage diagnoses among Black/African American and Latina/Hispanic women 
[27,38] African American/Black AYAs in Texas were 31% (p-value<0.000, 95% CI 
1.09, 1.58) more likely to be diagnosed at a later stage than White AYAs. Being an AYA 
woman of Hispanic/Latina ethnicity was associated with a 36% increased risk of being 
diagnosed at a later stage of breast cancer (p-value<0.00, 95% CI 1.16,1.59).  
Distance from breast clinical trials was significantly associated with a 102% (p-
value<0.000, 95% CI 1.09,1.58) greater likelihood of a later stage breast cancer 
diagnosis for those living at distances between 45 and 100 miles. While the trend did not 
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hold for all travel distances, the likelihood of a later stage diagnoses as compared to an 
earlier stage for those AYAs living more than 200 miles was 49% (p-value 0.020, 95% 
CI 1.06,2.09). While our study was not able to report on risk factors for breast cancer 
sub-types including triple negative breast cancers among Texas AYAs, these data are 
now being collected by the TCR and should be on a research agenda for the near future.  
My findings add to the growing body of literature identifying the need for more 
effective mechanisms to recruit AYAs into clinical and supportive care cancer research 
trials. AYAs have traditionally had low participation rates in cancer clinical trials. For 
breast cancer patients, the use of patient-friendly online matching system offered by 
BreastCancerTrials.org may be an effective method of increased recruitment for AYAs. 
However, additional opportunities may exist in emerging patient-centered recruiting 
efforts including online databases and data linkages for trial recruitment.   
Our results that uninsured AYA women, including those who self-pay, were 70% 
more likely to be diagnosed at a later stage of breast cancer (p-value <0.000, 95% CI 
1.31, 2.20) are consistent with a recent study by Keegan et al. that suggests that lack of 
insurance is a significant barrier overall for AYAs diagnosed with cancer [20].  It 
appears likely that the lack of health insurance among AYA breast cancer patients may 
be a factor in delayed diagnosis and, for more advanced cancers, the lack of progress in 
extending survival and reducing mortality. It is unclear if the Patient Protection and 
Affordable Care Act will provide sufficient increased coverage among Texas AYAs, 
especially those who are Black or Latina and who may live at significant distances from 
care, including clinical trials. These are the AYA women who are perhaps most 
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vulnerable to higher risk breast cancer sub-types and delays in diagnosis. This is an area 
for future research to determine policy and system approaches to address this type of 
disparity, including mechanisms to support more efficient referral mechanisms to tertiary 
cancer centers that are more likely to offer supportive navigation, multidisciplinary care, 
and a range of breast cancer trials. 
Many of the areas of practice and research gaps that were explored in the AYA 
breast cancer study were present in the qualitative evaluation research for the ACCESS 
AYA project. The stakeholders in the qualitative study identified as valuable the access 
to educational information related to late effects and improved models of transitioning 
from treatment into community-based care. The survivors’ interviews, especially, gave 
evidence of the perceived value and utility of survivorship care plans and the services of 
a nurse navigator in providing guidance on screening, access to health care, and 
insurance. The ACCESS AYA program evaluation findings were consistent with prior 
studies done by Zebrack et al. in identifying activities and factors that may enhance 
resilience and quality of life among AYA cancer survivors including the influence of 
peer social networks [50]. 
In efforts to improve survivorship care models, stakeholders in the ACCESS 
AYA evaluation identified gaps in training programs focused on the care of AYA 
patients including integrating information about fertility, palliative care, and more 
proactive approaches to helping patients understand the stressors and issues they may 
face as they transition out of cancer care into the “new normal” of survivorship.  
Research gaps that emerged from the evaluation study from across all of the stakeholder 
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groups include addressing lack of best practices, policies and systems approaches to gaps 
in psychosocial care, and socioeconomic consequences that appear to deeply affect 
younger people including impacts on career, education, family finances, and 
employment opportunities.  
 As I continued to identify the barriers and challenges associated with improving 
quality of life and the need for AYAs to engage in self-advocacy and self-management 
of cancer survivorship as a chronic disease, I initially hoped that mobile apps for cancer 
survivors would provide low cost, easily accessible information and opportunities for 
health behavior change interventions. While I found significant numbers of mHealth 
apps focused on cancer survivorship, for the most part the theory and evidence base for 
these mHealth applications to build upon the existing knowledge base of interventions 
was missing.  My conclusions about the potential for mHealth apps in cancer are similar 
to those stated by Bender et al. [63], that research and work needs to be done to develop 
theory and evidence-based cancer interventions using mobile technology.  
While I remain optimistic about the potential for mHealth, especially among 
younger populations like the AYA survivors, the reality is not yet meeting the promise. 
As the field of mHealth in cancer survivorship and other chronic diseases continues to 
mature and to take advantage of emerging technologies in mobile sensors and 
monitoring, we may see greater benefits. The possibilities for increased communication 
and information sharing through mHealth applications with regard to survivor/provider 
communications and transitions in care hold great potential.   
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The AYA survivors in the evaluation study evidenced a strong desire for 
advocacy and engagement. I believe that this type of advocacy can be a motivation and a 
resource for engaging more AYA survivors in research with mHealth apps as technology 
facilitators. Cancer is a life-changing experience, and in making meaning of their 
experiences younger cancer survivors often seek a way to give back and express their 
gratitude [82]. Use of mobile resources, including apps and sensors could be leveraged 
to capture important and useful research data for survivor care patterns and assessments 
including location-based information. Engaging young, or even older cancer survivors in 
well-structured community-based participatory research, as a form of “crowd-sourcing” 
may offer a low cost way to capture information on important behavioral and 
psychosocial data on survivorship topics such as pain, cognitive function, and lifestyle 
interventions.  
The AYA population covers a broad age range and a number of different types of 
cancer. The experiences of the AYA survivors vary greatly depending on the type of 
cancer, the age at which they are diagnosed, and treatment they experience.  
Significant future opportunities exist in identifying and reducing the multifactorial 
disparities and risk factors experienced by AYA cancer survivors through the 
development of theory and evidence-based interventions. The limitations of the findings 
with regard to Texas AYA breast cancer patients include a lack of behavioral data on the 
individual patients and more precise information on their educational and socio-
economic status. For example, my findings suggested that the women who lacked 
insurance at time of diagnosis had a higher risk of being diagnosed at a later stage. It was 
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notable that no payer information was available for over 37% of the AYA breast cancer 
patients. Risk factors such as the information on having insurance at time of diagnosis 
can mask what happens over time during a survivor’s transition through cancer care and 
into survivorship. Many of the costs of cancer are not covered by insurance and 
insurance status may change during or after cancer care due to job loss, divorce, or other 
factors [83]. Some patients may start and then defer or delay treatment due to costs. Thus 
without detailed information on the costs of care and treatment it is difficult to ascertain 
the degree to which having insurance at diagnosis is a protective factor. 
 The focus on the Texas AYA population is a limit to the generalizability of the 
AYA breast cancer risk assessments. Texas has a broad and diverse population spread 
across great distances. The relative percentage of the breast cancer population with 
access to nearby breast cancer trials may be very different for other regions of the 
country. Also, Texans may be more likely to travel larger distances for care, as longer 
travel distances are an aspect of the state’s geography.  
 In the evaluation of the ACCESS AYA program, the study team was limited by 
the time and costs to a fairly small sample size of stakeholders. It is possible that 
engagement in a larger group would have provided added insights. However, the depth 
and engagement with our stakeholder subjects provided information and insights similar 
to prior qualitative and quantitative studies on educating health care professionals and 
young adults with regard to cancer survivorship issues and concerns [49].  
 In my assessment of mHealth apps, we relied on the theoretical framework 
developed by Webb and Mitchie [69]. The analysis of the mHealth apps by coding them 
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for health behavior change techniques could be perceived as limiting. It is possible that 
deeper insights into the applicability and potential for behavior change techniques may 
be different if evidence and information is gathered on the actual use of the mHealth 
apps.   
These studies add to the evidence that, despite recent improvements and greater 
attention paid to this unique population, AYA cancer survivors continue to face 
challenges in cancer survivorship.  My analysis of Texas AYA breast cancer patients 
contributes to the understanding of variability in demographic and clinical risk factors 
and suggests opportunities for studies of AYA breast cancer patients that would include 
information on hormone receptor status as well as lifestyle factors. The evaluation of the 
ACCESS AYA project suggests that additional survivor and professional education on 
late effects, both psychosocial and physical, are needed as more survivors, AYAs, as 
well as older adults will transition into community care. Evidence and research on the 
potential for mHealth applications in cancer survivorship health and behavioral 
interventions, patient/provider engagement, and in clinical and community-based 
participatory research is in its infancy. As use of mHealth apps expands with greater use 
of sensors and monitoring, significant attention is needed to ensure that the designers 
and builders apply the knowledge and power of theoretical health behavior and 
communication frameworks.   
 My findings suggest that there remain significant gaps and disparities among 
AYA cancer survivors that offer direction for future investments in research including 
the following: 
  103
1) Geographic and socioeconomic risk factors that may affect how and where AYAs 
seek treatment and the quality of treatment they receive; 2) Increased efforts to identify 
genetic and familial risks that may predispose AYAs to cancer, such as young women 
with higher risks of triple negative breast cancers, and the development of evidence and 
risk-based strategies; 3) Psychosocial and developmental issues that result from 
treatments that may result in difficulties in education and underemployment of AYA 
survivors; and 4) Greater collaboration across disciplines of care including oncologists, 
community-based providers and navigators, and nurses including collaborative education 
and knowledge sharing for transitions. 
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APPENDIX A 
 
Table A.1 Early Stage Trial Listing  
 
 
 
Trial Number  Trial Name  Trial Location City/State 
NCT00555152 
 
Lapatinib in 
Treating Women 
With Ductal 
Carcinoma In 
Situ of the Breast 
Dan L. Duncan Cancer Center at 
 Baylor College of Medicine 
M. D. Anderson Cancer Center at 
 University of Texas 
 
Houston, TX 
Houston, TX 
NCT00669747 
 
A Phase II 
Randomized 
Study Of 
Intraductal 
Carboplatin In 
Women With 
Ductal 
Carcinoma In 
Situ   
M. D. Anderson Cancer Center at  
University of Texas 
 
Houston, TX 
NCT00677430 
 
Multimodality 
Anthropometric 
Analysis for 
Quantitative 
Assessment of 
Outcomes in 
Breast 
Reconstructive 
Surgery  
 
M. D. Anderson Cancer Center at 
University of Texas 
 
Houston, TX 
NCT00999804 
 
TBCRC 023: A 
Randomized 
Multicenter 
Phase II 
Neoadjuvant 
Trial of Lapatinib 
Plus 
Trastuzumab, 
With or Without 
Endocrine 
Therapy for 12 
Weeks vs. 24 
Weeks in 
Patients With 
HER2 
Overexpressing 
Breast Cancer  
 
Dan L. Duncan Cancer Center at 
Baylor College of Medicine 
 
Houston, TX 
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Trial Number  Trial Name Locations City/State 
NCT01008150 
 
A Phase II 
Randomized 
Clinical Trial 
Evaluating 
Neoadjuvant 
Therapy 
Regimens With 
Weekly 
Paclitaxel and 
Neratinib or 
Trastuzumab 
Followed by 
Doxorubicin 
and 
Cyclophospham
ide With 
Postoperative 
Trastuzumab in 
Women With 
HER2+ Disease 
 
M. D. Anderson Cancer Center at 
University of Texas 
 
Houston, TX 
NCT01036087 
 
Phase II Study 
of 
Panitumumab, 
Nab-paclitaxel, 
and Carboplatin 
for Patients 
With Primary 
Inflammatory 
Breast Cancer 
(IBC) Without 
HER2 
Overexpression 
 
M. D. Anderson Cancer Center at 
University of Texas 
 
Houston, TX 
NCT01042379 
 
I-SPY 2 Trial 
(Investigation of 
Serial Studies 
to Predict Your 
Therapeutic 
Response With 
Imaging And 
molecular 
Analysis  
 
M. D. Anderson Cancer Center at 
University of Texas 
Simmons Comprehensive Cancer 
Center at University of Texas 
Southwestern Medical Center - Dallas 
 
 
Houston, TX 
 
Dallas, TX 
NCT01162200 
 
Partial Breast 
Irradiation (PBI) 
for Early Stage  
 
Simmons Comprehensive Cancer 
Center at University of Texas 
Southwestern Medical Center - Dallas 
 
Dallas, TX 
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Trial Number Trial Name Location City/State 
NCT01245712 
 
Assessing the 
Cosmesis and 
Toxicity of 
Partial Breast 
Irradiation Using 
Proton Beam 
Irradiation 
(NCT01245712) 
 
M. D. Anderson Cancer Center at 
University of Texas 
 
Houston, TX 
NCT01266642 
 
Randomized 
Trial of Hypo 
fractionated 
Whole Breast 
Irradiation 
Versus 
Conventionally 
Fractionated 
Whole Breast 
Irradiation for 
Ductal 
Carcinoma in 
Situ and Early 
Invasive Breast 
Cancer 
 
University of Texas M.D. Anderson  
Cancer Center 
Harrington Cancer Center 
Doctor's Hospital of Laredo 
Southwest Oncology Group 
St. Joseph Regional Cancer Center 
Dan L. Duncan Cancer Center 
 at Baylor College of Medicine 
All Saints Episcopal Hospital -  
Fort Worth 
 
Simmons Comprehensive Cancer  
Center at University of Texas  
Southwestern Medical Center - Dallas 
University Hospital - San Antonio 
Texas Tech University Health Sciences Center 
University of Texas Health Science 
 Center at San Antonio 
Covenant Medical Center 
University of Texas Medical Branch 
Cancer Therapy and Research  
Center 
Baylor Medical Center at Irving 
Methodist Hospital 
Houston  
Amarillo 
Laredo 
San 
Antonio 
Bryan 
Houston 
Fort Worth 
Dallas 
San 
Antonio 
Lubbock 
San 
Antonio 
 
Lubbock 
Galveston 
San 
Antonio 
Irving 
Houston 
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Table A.2 Late Stage Trial Listing 
 
Trial Number Trial Name Locations City/State 
NCT00003135 Whole Body Hyperthermia 
Combined With 
Chemotherapy in Treating 
Patients With Metastatic 
Breast, Ovarian, 
Endometrial, or Cervical 
Cancer (NCT00003135) 
 University of Texas 
Health Science Center at 
Houston 
Houston ,TX 
NCT00570908 A Phase 2 Trial of 
Capecitabine Concomitantly 
With Whole Brain 
Radiotherapy(WBRT) 
Followed by Capecitabine 
and Sunitinib for Central 
Nervous Suste, (CNS) 
Metastases in Breast Cancer 
(NCT00570908) 
 Dan L. Duncan Cancer 
Center at Baylor College 
of Medicine 
Houston, TX 
NCT00929214 Aggressive Local Therapy 
for Limited Bone-Only 
Metastasis to Improve 
Progression-Free Survival in 
Breast Cancer Patients 
(NCT00929214) 
 M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
NCT00968968 A Randomized, Open-label 
Study of Lapatinib Plus 
Trastuzumab Versus 
Trastuzumab as Continued 
HER2 Suppression Therapy 
 GSK Investigational Site 
M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
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Trial Number Trial Name Locations City/State 
NCT01048099 Use of the PRO Onc Assay 
to Assess HER2 
Amplification and Activation 
in Patients With Metastatic 
Breast Cancer Whose 
Tumors Are HER2-Negative 
by Standard FISH Testing 
(NCT01048099) 
 Center for Cancer and 
Blood Disorders - Fort 
Worth 
Ft. Worth, TX 
NCT01061840 Phase I Trial of Bi-
shRNAfurin and GMCSF 
Augmented Autologous 
Tumor Cell Vaccine for 
Advanced Cancer 
(NCT01061840) 
 Mary Crowley Medical 
Research Center at 
Sammons Cancer Center 
Dallas, TX 
NCT01149083 Veliparib With or Without 
Carboplatin in Treating 
Patients With Stage III or IV 
Breast Cancer 
(NCT01149083) 
 M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
NCT01156870 Dose Escalation, Safety and 
Pharmacokinetic, First in 
Man Study, of SAR566658 
Administered as a Single 
Agent by Intravenous 
Infusion Every 3 Weeks in 
Adult Patients With DS6-
positive and Refractory Solid 
Tumors (NCT01156870) 
(NCT01156870) 
 Investigational Site 
Number 840001 Audie 
Murphy VA 
San Antonio, 
TX 
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Trial Number Trial Name Locations City/State 
NCT01177397 A Phase 1/2, Multi-Center, 
Open-Label, Dose Finding 
Study to Assess the Safety, 
Tolerability, 
Pharmacokinetics and 
Preliminary Efficacy of the 
mTOR Kinase Inhibitor CC-
223 Administered Orally to 
Subjects With Advanced 
Solid Tumors,...  
(NCT01177397) 
 Mary Crowley Medical 
Research Center at 
Sammons Cancer Center 
Dallas, TX 
NCT01197170 Hormone Receptor Positive 
Disease Across Solid Tumor 
Types: A Phase I Study of 
Single-Agent Hormone 
Blockade and Combination 
Approaches With Targeted 
Agents to Provide Synergy 
and Overcome Resistance 
(NCT01197170) 
 M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
NCT01221870 A Phase II Study of 
Tesetaxel as First-line 
Therapy for Subjects With 
Metastatic Breast Cancer 
(NCT01221870) 
 Texas Oncology, PA at 
Charles A. Sammons 
Cancer Center 
Dallas, TX 
NCT01231802 A Comparative, Multicenter, 
Open-Label, Randomized, 
Phase 2 Study of the Safety 
and Antitumor Activity of 
Oral Eniluracil + 5 
Fluorouracil + Leucovorin 
Versus Capecitabine 
Monotherapy in Subjects 
With Metastatic Breast 
Cancer (NCT01231802) 
 Methodist Hospital Houston, TX 
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Trial Number Trial Name Locations City/State 
NCT01242800 Early Surgery or Standard 
Palliative Therapy in 
Treating Patients With Stage 
IV Breast Cancer 
(NCT01242800) 
 Simmons 
Comprehensive Cancer 
Center at University of 
Texas Southwestern 
Medical Center  
Methodist Hospital 
University of Texas  
 
Health Center at Tyler 
 
University of Texas M.D. 
Anderson Cancer Center 
 
Scott and White Cancer I 
 
Baylor Medical Center at  
University of Texas 
Medical Branch 
UTMB Cancer Center at 
Victory Lakes 
 
Doctor's Hospital of 
Laredo 
 
Dallas, TX 
 
 
 
 
Houston, TX 
 
 
Tyler, TX 
 
Houston, TX 
 
Temple, TX 
 
 
Galveston, TX 
 
 
Clear Lake, 
TX 
 
Laredo, TX 
 
NCT01262027 A Phase II Study of TKI258 
(Dovitinib Lactate) as 
Salvage Therapy in Patients 
With Stage IV HER2-
negative Inflammatory 
Breast Cancer (IBC) and 
Local or Distant Relapse  
 M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
NCT01325207 Phase I/II Dose Escalation 
Trial to Assess Safety of 
Intrathecal Trastuzumab for 
the Treatment of 
Leptomeningeal Metastases 
in HER2 Positive Breast 
Cancer  
 Texas Oncology - 
Midtown Austin 
Austin, TX 
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Trial Number Trial Name Locations City/State 
NCT01325441 A Phase Ib/II Clinical Study 
of BBI608 Administered With 
Paclitaxel in Adult Patients 
With Advanced Malignancies 
(NCT01325441) 
Tyler Cancer Center 
Texas Oncology- Fort 
Worth 
Texas Oncology- Baylor 
Charles A. Sammons 
Cancer Center 
Tyler, TX 
Ft. Worth TX 
Dallas, TX 
 
NCT01332630 A Phase II Open-Label 
Study of TPI 287 in Patients 
With Breast Cancer 
Metastatic to the Brain 
(NCT01332630) 
 M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
NCT01351103 A Phase I, Open-label, Dose 
Escalation Study of Oral 
LGK974 in Patients With 
Melanoma and Lobular 
Breast Cancer 
(NCT01351103) 
 M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
NCT01411410 A Phase 1 Study of BAY80-
6946 (Phosphatidylinositol 
3΄-Kinase Inhibitor) in 
Combination With Paclitaxel 
in Subjects With Advanced 
Solid Malignancy 
(NCT01411410) 
 M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
NCT01421524 A Phase 1a/1b, Multi Center, 
Open-Label, Dose-Finding 
Study to Assess the Safety, 
Tolerability, 
Pharmacokinetics and 
Preliminary Efficacy of the 
Pleiotropic Pathway Modifier 
CC-122 Administered Orally 
to Subjects ... 
(NCT01421524) 
South Texas Accelerated 
Research Therapeutics 
San Antonio, 
TX 
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Trial Number Trial Name Locations City/State 
NCT01434303 Entinostat and Lapatinib 
Ditosylate in Patients With 
Locally Recurrent or Distant 
Relapsed Metastatic Breast 
Cancer Previously Treated 
With Trastuzumab 
(NCT01434303) 
 University of Texas M.D. 
Anderson Cancer Center 
Houston, TX 
NCT01437566 A Phase II, Double-Blind, 
Placebo Controlled, 
Randomized Study of GDC-
0941 or GDC-0980 With 
Fulvestrant Versus 
Fulvestrant in Advanced or 
Metastatic Breast Cancer in 
Patients Resistant to 
Aromatase Inhibitor Therapy 
(NCT01437566) 
 University of Texas M.D. 
Anderson Cancer Center 
Houston, TX 
NCT01446016 Phase II Study of The 
Efficacy And Safety of 
Chloroquine (C) in 
CombinAtion With Taxane  
Methodist Hospital Houston, TX 
NCT01494662 A Phase II Trial of HKI-272 
(Neratinib) for Patients With 
Human Epidermal Growth 
Factor Receptor 2 (HER2)-
Positive Breast Cancer and 
Brain Metastases 
(NCT01494662) 
 Dan L. Duncan Cancer 
Center at Baylor College 
of Medicine 
Houston, TX 
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Trial Number Trial Name Locations City, State 
NCT01506609 A Randomized, Phase 2 
Study of the Efficacy and 
Tolerability of Veliparib in 
Combination With 
Temozolomide or Veliparib 
in Combination With 
Carboplatin and Paclitaxel 
Versus Placebo Plus 
Carboplatin and Paclitaxel in 
Subjects With BRCA1 or 
BRCA2 (NCT01506609) 
 M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
NCT01516307 A Double-blind, Randomized 
Trial of Active 
Immunotherapy With Globo 
H-KLH (OPT-822) in 
Subjects With Metastatic 
Breast Cancer 
(NCT01516307) 
 M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
NCT01528345 A Multicenter, Randomized, 
Double Blind, Placebo 
Controlled, Phase II Trial 
Evaluating the Safety and 
Efficacy of Dovitinib 
Combined With Fulvestrant, 
in Postmenopausal Patients 
With HER2- and HR+ Breast 
Cancer That Have... 
(NCT01528345) 
 Cancer Care Centers of 
South Texas  
San Antonio, 
TX 
NCT01529593 
Phase I Study of 
Temsirolimus in 
Combination With Metformin 
in Patients With Advanced 
Cancers (NCT01529593) 
M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
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Table A.2 Continued 
 
Trial Number  Trial Name Locations City/State 
NCT01548144 A Two Steps Phase I Trial of 
Pazopanib or Pemetrexed in 
Combination With Crizotinib 
Followed by the Triplet, 
Crizotinib Plus Pazopanib 
Plus Pemetrexed in Patients 
With Advanced Malignancies 
(NCT01548144) 
M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
NCT01556789 Phase 1 Study of ONT-10, a 
Liposomal MUC1 Cancer 
Vaccine, in Patients With 
Solid Tumors 
(NCT01556789) 
 Mary Crowley Medical 
Research Center at 
Sammons Cancer Center 
Dallas, TX 
NCT01572727 A Randomized, Double-
blind, Placebo Controlled, 
Phase II Study of BKM120 
Plus Paclitaxel in Patients 
With HER2 Negative 
Inoperable Locally Advanced 
or Metastatic Breast Cancer, 
With or Without PI3K 
Pathway Activation. 
(NCT01572727) 
 Texas Oncology, P.A. 
Central Austin Cancer 
Center 
Baylor Health Care 
System/Sammons 
Cancer Center Baylor 
Texas Oncology 
Simmons Comprehensive 
Cancer Center at 
University of Texas 
Southwestern Medical 
Center - D 
 
Austin, TX 
 
 
Dallas, TX 
 
 
 
Dallas, TX 
 
 
NCT01576666 A Phase Ib, Multi-center, 
Open Label, Dose 
Escalation Study of Oral 
LDE225 in Combination With 
BKM 120 in Patients With 
Advanced Solid Tumors 
(NCT01576666) 
 Sammons Cancer 
Center - Texas Oncology 
SC-2 
M. D. Anderson Cancer 
Center at University of 
Texas 
Texas Oncology, P.A. SC 
Dallas, TX 
 
Houston, TX 
 
 
Austin, TX 
 
 
 
 
 
 
 
 
  123
Table A.2 Continued 
 
Trial Name Trial Number 
 
Locations  City/State 
NCT01610284 A Phase III Randomized, 
Double Blind Placebo 
Controlled Study of BKM120 
With Fulvestrant, in 
Postmenopausal Women 
With Hormone Receptor-
positive HER2-negative 
Locally Advanced or 
Metastatic Breast Cancer 
Which Progressed ... 
(NCT01610284) 
 Oncology Consultants 
Oncology Consultants, 
P.A. 
Texas Oncology, P.A. TX 
Onc - Med City Dallas 
CTRC Cancer Center 
 
 
Houston, TX 
 
 
Dallas, TX 
 
San Antonio, 
TX 
NCT01623349 Phase I Study of the Oral 
PI3kinase Inhibitor BKM120 
and the Oral PARP Inhibitor 
Olaparib in Patients With 
Recurrent Triple Negative 
Breast Cancer or Recurrent 
High Grade Serous Ovarian 
Cancer (NCT01623349) 
 M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
NCT01624441 A Phase 1 Study With Dose 
Expansion of Dinaciclib 
(SCH 727965) in 
Combination With Epirubicin 
in Patients With Metastatic 
Triple Negative Breast 
Cancer (NCT01624441) 
University of Texas M.D. 
Anderson Cancer Center 
Houston, TX 
NCT01625234 Phase 1, First-in-Human, 
Dose-Escalation Study to 
Evaluate the Safety, 
Tolerability, and 
Pharmacokinetics of X-396 
in Patients With Advanced 
Solid Tumors 
(NCT01625234) 
 M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
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Table A.2 Continued 
 
Trial Number Trial Name Locations City, State 
NCT01627067 Circulating FGF21 Levels 
and Efficacy of Exemestane, 
Everolimus and Metformin in 
Postmenopausal Women 
With Hormone Receptor 
Positive Metastatic Breast 
Cancer and BMI >/= 25 
(NCT01627067) 
 M. D. Anderson Cancer 
Center at University of 
Texas 
Houston, TX 
NCT01633060 A Phase III Randomized, 
Double Blind, Placebo 
Controlled Study of BKM120 
With Fulvestrant, in 
Postmenopausal Women 
With Hormone Receptor-
positive HER2-negative AI 
Treated, Locally Advanced 
or Metastatic Breast Cancer 
Who Progressed on... 
(NCT01633060) 
 US Oncology, 
Incorporated - Central 
Office 
Methodist Hospital 
Texas Tech University 
Health Science Center 
Dept of Texas Tech 
Texas Oncology, P.A. 
Texas Oncology - Fort 
Worth (3 
Texas Oncology, PA at 
Charles A. Sammons 
Cancer Center 
Simmons Comprehensive 
Cancer Center at 
University of Texas 
Southwestern Medical 
Center - Dallas 
 
Houston, TX 
 
 
Houston, TX 
Lubbock, TX 
 
 
 
Fort Worth TX.
Dallas, TX 
 
 
Dallas, TX 
 
 
 
NCT01663727 A Phase III, Randomized, 
Double-Blind, Placebo-
Controlled, Multicenter Study 
To Evaluate the Efficacy and 
Safety Of Bevacizumab, and 
Associated Biomarkers, In 
Combination With Paclitaxel 
Compared With Paclitaxel 
Plus Placebo... 
(NCT01663727) 
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Table A.2 Continued 
 
Trial Number Trial Name Locations City/State 
NCT01677455 An Open Label Multicenter 
Phase 2 Window of 
Opportunity Study 
Evaluating Ganetespib 
(STA-9090) Monotherapy in 
Women With Previously 
Untreated Metastatic HER2 
Positive or Triple Negative 
Breast Cancer 
(NCT01677455) 
 MD Anderson Cancer 
Center  
Houston, TX 
NCT01698918 An Open-label, Phase II, 
Single-arm Study of 
Everolimus in Combination 
With Letrozole in the 
Treatment of 
Postmenopausal Women 
With Estrogen Receptor 
Positive Metastatic Breast 
Cancer (NCT01698918) 
East Texas Hematology 
& Oncology Clinic, PA 
Tyler, TX 
NCT01783444 A Phase II Study of 
Everolimus in Combination 
With Exemestane Versus 
Everolimus Alone Versus 
Capecitabine in Advance 
Breast Cancer. 
The Center for Cancer 
and Blood Disorders 
Dept. of The Ctr for C & 
BD 
Ft. Worth. TX 
NCT01802970 Pilot Safety and Blood 
Immune Cell 
Transcriptional Profiling 
Study of Weekly Nab 
Paclitaxel Plus Anakinra in 
Metastatic Breast Cancer 
Patients (NCT01802970) 
 Baylor University Medical 
Center - Dallas 
Dallas, TX 
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Table A.2 Continued 
 
Trial Name Trial Number Locations City/State 
NCT01808573 A Study of Neratinib Plus 
Capecitabine Versus 
Lapatinib Plus Capecitabine 
in Patients With HER2+ 
Metastatic Breast Cancer 
Who Have Received Two or 
More Prior HER2 Directed 
Regimens in the Metastatic 
Setting (NCT01808573) 
 Houston Cancer Institute Houston, TX 
NCT01818999 A Phase II Trial Of 
Ixabepilone and Stereotactic 
Body Radiation Therapy 
(SBRT) For Patients With 
Triple Negative Metastatic 
Breast Cancer 
(NCT01818999) 
 Simmons 
Comprehensive Cancer 
Center at University of 
Texas 
Dallas, TX 
NCT01881230 A Phase 2/3, Multi-center, 
Open-label, Randomized 
Study of Weekly Nab-
paclitaxel in Combination 
With Gemcitabine or 
Carboplatin, Compared to 
the Combination of 
Gemcitabine and 
Carboplatin, as First-line 
Treatment in Female 
Subjects ... (NCT01881230) 
Center for Cancer and 
Blood Disorders - Fort 
Worth 
Texas Oncology, PA at 
Charles A. Sammons 
Cancer Center 
Texas Oncology, PA at 
Presbyterian Hospital 
Dallas 
Ft. Worth, TX 
 
 
Dallas, TX 
 
 
Dallas, TX 
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Table A.2  Continued 
 
Trial Number Trial Name Locations City/State 
NCT01945775 A Phase 3, Open-Label, 
Randomized, Parallel, 2-
Arm, Multi-Center Study of 
BMN 673 Versus Physician's 
Choice in Germline BRCA 
Mutation Subjects With 
Locally Advanced and/or 
Metastatic Breast Cancer, 
Who Have Received No 
More Than 2 Prior 
Chemotherapy Received 
(NCT01945775) 
 Texas Oncology P.A. 
 
 Texas Oncology P.A. 
 
 Texas Oncology P.A. 
Dallas, TX 
 
Houston, TX 
 
Austin, TX 
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APPENDIX B 
 
 
Appendix B.1 ACCESS AYA PEARL 
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B.2 PEARL Tab for Physician Offices  
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B.3 ACCESS AYA Recruiting Script and Consent 
 
Email Script for Seton ACCESS AYA CPRIT Grant Evaluation Participants 
 
 
 
Seton Healthcare Family Oncology Network staff members identified you as a 
potential interviewee for an evaluation of Seton’s Adolescent and Young Adult Cancer 
Survivor grant project. The grant project was funded by the Cancer Prevention and 
Research Institute of Texas and you can find information about the project on Seton’s 
Survivorship website pages for patients and providers. 
  
http://www.seton.net/medical_services_and_programs/cancer_care/cancer_survi
vorship/ 
  
Texas A&M’s School for Rural Public Health (SRPH) is conducting the 
evaluation. The goal of the evaluation is to learn more about how the grant activities 
and materials are being used. 
 
The purpose of this email is to find out if you are willing to be interviewed as 
part of the evaluation and, if you are, to gain your consent and capture some basic 
background information. Attached to this email are an information sheet about the 
project and additional materials about confidentiality and consent. 
 
If you are willing to participate, please follow this link to consent and to provide 
demographic information and information about how best to contact you. (www…link 
to be provided)  
 
 If you agree to be interviewed we will set up a specific time and date for an 
interview call that will last between 20-30 minutes. Either Dr. Marcia Ory or Ms. Debra 
Kellstedt from Texas A&M will conduct the interviews. 
 
All the information you provide will be kept strictly confidential and will not be 
associated with your name. Your responses will be combined with responses of other 
interview participants. We will not share your personal information with any other 
organization or individuals. The data collected during the interviews will be stored and 
secured at SRPH on a portable hard drive or in text documents in a locked file. In the 
event of any publication or presentation resulting from this research, no personally 
identifiable information will be disclosed. 
 
Thank you for your time and consideration.  If you do not click on the link for 
consent and information, we will delete your name and information from our files and 
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will not retain any record that you were considered as a potential interviewee for this 
evaluation study. 
 
Please feel free to contact either Christopher Hamilton or me, Deborah Vollmer 
Dahlke, if you have any questions about the project or your participation as an 
interview candidate.  You may also contact Dr. Marcia Ory, the principal investigator 
on the project.  We have provided all of our emails and phone numbers below for your 
convenience.  
 
 
Thank you for your consideration. 
 
Kind regards, 
 
Deborah Vollmer Dahlke 
deborahvd@gmail.com 
512.699.4493 
 
Christopher M. Hamilton 
cmhamilton@seton.org 
512. 705.5600 
 
 
Dr. Marcia Ory 
mory@srph.tamhsc.edu 
979 458 1373 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  133
B.4 Facebook Recruiting Script  
 
ACCESS AYA Survivor Recruitment on Facebook Group Site  
 
You are invited to participate in a research project to evaluate Seton’s AYA survivorship 
education programs.  You must be 18 years or older to participate.  You will be asked to 
fill out a few demographic questions an online survey and to schedule a 20-30 minute 
phone interview to answer questions about AYA educational programs.    
 
Survey Link 
All the information you provide will be kept strictly confidential. Your responses will be 
combined with responses of other participants in the evaluation. We will not share your 
personal information with any other organization or individuals. 
 
To learn more about participation in the evaluation, please contact Deborah Vollmer 
Dahlke at 512.699.4493 or at deborahvd@gmail.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  134
B.5 Interview Guide: AYA Survivors 
 
Interview Guide for CPRIT ACCESS AYA Grant 
Cancer Survivor/Family Members/ Caregivers 
 
You previously gave consent for this brief interview regarding the impact and outcomes 
of Seton’s ACCESS AYA grant from CPRIT.  The purpose of the grant was to provide 
education for both professionals and the public regarding the unique needs of Adolescent 
and Young Adult (AYA) cancer survivors (ages 15-39).  
 
I will be asking you a series of open-ended questions so you can share your thoughts 
about and experiences with the AYA survivorship education programs at Seton. 
There are no right or wrong answers.  You do not need to answer any interview 
questions that you do not wish to answer.  Your responses will be kept confidential, and 
reports will not identify any individual respondents. 
Are you comfortable with our recording this conversation? (If respondent says “yes’ 
start recording, if “no,” then take notes but do not record).  
1) In what ways have Seton’s education programs on Adolescent and Young Adult 
cancer survivorship helped you as a survivor (or survivors caregiver/family 
member)?  
2) Have you shared any of the information or education materials, including the 
videos or the AYA app, with other AYA survivors?  What about caregivers or 
family members? Is there an anecdote or story you can share? 
3) In what ways, if any, has information or educational materials about AYA cancer 
survivorship helped you?  For example learning about healthy diets or physical 
activity for AYA survivors?   
4) What barriers or challenges are you aware of regarding how AYA cancer 
survivors are cared for or treated in Central Texas?    
5) Has the information or education regarding AYA cancer survivors changed how 
you think about or treat other cancer survivors?   If so, can you provide some 
examples? 
6) What opportunities or challenges do you believe exist in sustaining or expanding 
programs for AYAs?  
7) Do you have any additional thoughts or information you would like to share as 
part of this evaluation of the ACCESS AYA grant?   
 
Thank you for your time.   
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B.6 Interview Guide: Cancer Advocates  
Interview Guide for CPRIT ACCESS AYA Grant 
Cancer Advocates/Community Partners  
 
You previously gave consent for this brief interview regarding the impact and outcomes 
of Seton’s ACCESS AYA grant from CPRIT.  The purpose of the grant was to provide 
education for both professionals and the public regarding the unique needs of Adolescent 
and Young Adult (AYA) cancer survivors (ages 15-39).  
 
I will be asking you a series of open-ended questions so you can share your thoughts 
about and experiences with the AYA survivorship education programs at Seton. 
There are no right or wrong answers.  You do not need to answer any interview 
questions that you do not wish to answer.  Your responses will be kept confidential, and 
reports will not identify any individual respondents. 
Are you comfortable with our recording this conversation? (If respondent says “yes’ 
start recording, if “no” then take notes but do not record).  
1) In what ways have Seton’s professional and patient education programs on 
Adolescent and Young Adult Cancer helped you in your work as a cancer 
advocate?  
2) Can you give examples of how you have shared educational materials or 
information on the AYA cancer survivorship with your staff or your 
constituents/stakeholders?  Is there an anecdote or story you can share?  
3) In what ways, if any, has information or educational materials about AYA cancer 
survivors changed they way in which you do your work as an advocate?   
4) What barriers or challenges are you aware of regarding how AYA cancer 
survivors are cared for or treated in Central Texas? 
5) Has the information or education regarding AYA cancer survivors changed how 
you think about or treat other cancer survivors?   If so, can you provide some 
examples? 
6) What opportunities or challenges do you believe exist in sustaining or expanding 
programs for educating healthcare professionals about AYAs?  
7) What opportunities or challenges do you believe exist in sustaining or expanding 
programs for educating AYA cancer survivors and their families/caregivers? 
8) Do you have any additional thoughts or information you would like to share as 
part of this evaluation of the ACCESS AYA grant?   
 
Thank you for your time.   
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B.7 Interview Guide: Healthcare Professionals 
Interview Guide for CPRIT ACCESS AYA Grant 
Healthcare Professionals Interview Guide 
 
You previously gave consent for this brief interview regarding the impact and outcomes 
of Seton’s ACCESS AYA grant from CPRIT.  The purpose of the grant was to provide 
education for both professionals and the public regarding the unique needs of Adolescent 
and Young Adult (AYA) cancer survivors (ages 15-39).  
Consent previously provided   ☐ 
 
I will be asking you a series of open-ended questions so you can share your thoughts 
about and experiences with the AYA survivorship programs at Seton. 
There are no right or wrong answers.  You do not need to answer any interview 
questions that you do not wish to answer.  Your responses will be kept confidential, and 
reports will not identify any individual respondents. 
Are you comfortable with our recording this conversation? (If respondent says “yes’ 
start recording, if “no” then take notes but do not record).  
 
Yes ☐ 
No☐  
1) In what ways have Seton’s professional and patient education programs on 
Adolescent and Young Adult Cancer helped you understand the needs of these 
survivors? 
2) In what ways have you shared information on the AYA cancer survivor 
professional or patient education programs with your colleagues or staff? 
3) In what ways, if any, have information or educational materials about AYA 
cancer survivors changed the way in which you do your job?  
4) What barriers or challenges are you aware of regarding how AYA cancer 
survivors are cared for or treated in Central Texas? 
5) Has the information or education regarding AYA cancer survivors changed how 
you think about or treat other cancer survivors?   If so, can you provide some 
examples? 
6) What opportunities or challenges do you believe exist in sustaining or expanding 
programs for educating professionals about AYA cancer survivors?   
7) What opportunities or challenges do you believe exist in sustaining or expanding 
programs for educating AYA cancer survivors and their families/caregivers? 
8) Do you have any additional thoughts or information you would like to share as 
part of this evaluation of the ACCESS AYA grant? 
 
Thank you for your participation in this evaluation.
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APPENDIX C 
 
C.1 Coding Manual for Cancer Survivorship Apps 
Coding Manual for mHealth Behavioral Change Techniques in Cancer Survivorship 
Applications 
2014 
 
(An adapted version of the coding manual from Abraham C and Michie S.  A Taxonomy 
of Behavior Change Techniques use in Interventions: The Coding Manual) (2007)  
 
 
 
General Instructions for Coding Mobile Health Applications 
 
Please review the mHealth theory and behavior change taxonomy before coding the 
mobile health applications (mHealth apps). Discuss the techniques with co-coders to 
ensure that all coders interpret these materials, definitions, and techniques similarly.  
Conduct at least one practice coding session jointly with practice materials that are 
comparable (but different from) the final study materials and discuss these results with 
the team before beginning coding the study applications.  The following suggestions 
assume that the selection of the mHealth apps has already been made and that there is 
agreement among the team that all of the selected apps meet the stated criteria for 
inclusion in the study. 
 
Suggestions for optimal coding of health behavior mhealth apps: 
 
 Read all selection and coding material before coding. 
 Scan the different health behavior techniques presented in the coding table or 
Coding Scoring Sheet as these may differ by different types of apps. 
 Print out the Behavior Change Theory Definition Matrix and one Coding Scoring 
Sheet for each mHealth application. Put the name and source of the mHealth 
Application on the Coding Scoring Sheet 
 Start coding using the Coding Scoring Sheet. In case of any doubts between the 
techniques, please re-read the descriptions in the Theory Analysis and Definition 
Matrix 
 
After you have finished coding a mHealth application, please review the completed 
coding scoring sheet to make sure that you have scored the correct techniques and that 
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you have crossed out any techniques that are not use in the mHealth app under 
consideration. 
 
Request:  If you have suggestions for improvements or extensions of this coding manual 
please make them prior to beginning to code.   The coding manual is a work in progress, 
but for consistency in the study all coders need to begin and end with the same set of 
instructions. 
 
 
General Techniques in mHealth Applications 
 
Each scoring sheet has specific areas to score or annotate the presence of 
personalization, tailoring and participation.  
 
1.Personalization:  This is the provision of opportunities in the mHealth application to 
make elements of the application personal by the selection of tools or elements that are 
specific to the individual using the application.  An example would be the ability to 
select a disease type from among several available in the application and then to follow a 
specific path or set of tools or systems.  For example, being able to select “breast cancer” 
and then being provided sets of information specific to that type of cancer. Another 
example would be the ability to select to receive emails or texts of a specific nature. The 
choice of “yes” or “no” to a specific capability of the application would be considered 
personalization. 
 
 
2. Tailoring:  Coders are asked to annotate the score sheet for each mHealth application 
to indicate the app’s capability to include an intervention element or component that is 
specific to the characteristics of the person using the app.  Coders will be asked to score 
tailoring at three different levels in the initial assessment of the mHealth application (see 
Coding Scoring Sheet): 
1) Macro-tailoring at the group level.  In this instance the mHealth application can be 
adapted to adjust the intervention materials (including information) that the participant 
receives based on pre-tested characteristics.  For example an app may ask the user if 
he/she wishes to receive texts and/or assessments on diet, on exercise or smoking 
cessation.  
2) Meso-tailoring at the individual level. The amount or type of intervention depends on 
the individual needs of the participant.  For example, the participant could select 
between texts delivered once a day versus once a week.  
3) Micro-tailoring at the individual level.  Specific techniques in the mHealth application 
are tailored to the unique individual.  For example personalized goal setting and 
reporting tailored to the individual’s own needs and desires for physical activity.  Or 
GPS tracking and reporting of an individual’s walking or running activities.  
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Note that all of these general techniques may be used in one mHealth application. It is 
possible to have personalization, macro-, meso- and micro-tailoring techniques.  To 
score these general techniques the user or participant must be prompted to select an 
answer or provide input and make decisions in relation to the techniques. 
 
Specific Techniques By Determinant  
 
(Note: The examples given are specific to Cancer Survivorship, but can be adapted for 
other mHealth behavior techniques or topics.)  
 
Scoring is accomplished by marking the technique with a 1 or 0 in each element or 
section of the sheet.  A “1” indicates that the technique is present in the app, a “0” 
indicates that it is not present.  Personalization and tailoring scoring are provided as 
additional elements for each major determinant.  
 
Knowledge/Awareness 
 
1. Provide information about health behavior linkages.   
This section provides basic information about cancer and cancer survivorship, 
diagnosis, treatment, and/or availability of resources for clinical or non-clinical 
purposes.  If Personalized, the user is prompted to select or provide personal answers 
about type of cancer or stage of survivorship for example.  If Tailored, the user is 
required to select actions or elements specific to the intervention and the way 
information or activities are delivered to them as a result of these choices. 
 
2. Provide information on action/behavior and consequences. Information is 
provided about the cost/risks/benefits of action or inaction with respect to certain 
cancer survivorship behaviors. This scoring would also consider risk-communication 
strategies such as persuasive communications for example post treatment health 
screening, smoking cessation or adherence to flu-shot recommendations. 
 
Intention   
 
3.  Prompt Intention Formation.  The mHealth application includes suggestions for 
general behavior setting or formulating desired outcomes of a behavior for healthy 
survivorship, e.g., maintain a healthy weight, exercise regularly, eat 5 fruits and or 
vegetables daily.  It may be sometimes difficult to distinguish this from knowledge or 
awareness, but coders should look for language that indicates a specific action or 
activity.  Also, note that this technique is different from the actual setting of a goal or 
behavioral objective to facilitate change or adherence.  
 
Facilitation 
4.Provide Instruction. This technique involves telling or showing the user or participant 
ways to facilitate behavior change.  For example explaining “SMART” goal setting, or 
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how to use an app’s function to record questions on a mobile phone to ask a provider 
during an appointment.  The function of the instruction must be directly related to the 
improvement or behavior change, not for general use of the phone or the app. The 
facilitation may be in the form of written instructions, videos on YouTube that link from 
the app or images or cartoons that show a step-by-step instruction. 
 
5. Provide materials for education/information. The app provides the cancer survivor 
with specific materials and information that are suggestions for behavior change.  These 
differ from 1. Knowledge/Awareness in that the education is specific to a behavior 
change or an action.  For example, information on late effects of cancer treatment with 
prompts of when to contact a healthcare professional.  Another example would be 
educational information about health screenings specific to cancer survivors, for 
example breast mammograms for female survivors treated with whole body or mantle 
radiation starting at an early age.  
 
Intention 
 
6. Prompts for Specific Goal Setting.   This involves planning and setting a specific 
goal for what a person would do within a specific time and includes the specific context 
within which a behavior will be performed.   This would include selecting or writing 
down (micro-tailoring) of a specific goal for example setting a personal goal to “engage 
in physical activity for 150 minutes each week.”  Goal setting would include information 
on when, where, how to act in a specific behavior.  
 
7. Review of general or specific goals.  This would involve using the mHealth app in 
reconsideration of previously set goals or intentions and would require an indication of 
behavioral performance resulting from self-monitoring or tracking.  An example would 
be review of tracking a goal setting for intake of a specific amount of calories per day or 
number of minutes of physical activity for a week.  Another example might be noting a 
set of questions to be asked at a healthcare provider appointment regarding levels of pain 
or emotional distress during a past week or month.  
 
 Self-Efficacy 
 
8.  Prompt self-monitoring of behavioral goals.  The mHealth app suggests that the 
person record brief notes or keep a journal or diary to record behaviors and actions 
related to health behaviors.  Examples might be a journal of physical activity or pain or 
distress monitoring and actions taken to alleviate such as meditation or self-talk.  
 
9. Persuasion (verbal or written) The mHealth app delivers messages (may be 
personalized or tailored) designed to strengthen efficacy/control beliefs related to the 
execution of target or suggested behaviors. Examples might be often-used successful 
strategies (e.g., “park at the far end of the parking lot”, or “use the stairs instead of the 
elevator to increase physical activity”) or general tips.  New beliefs may be induced 
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and/or new information provided to the participant or user to create new control or 
behavior beliefs. 
 
Social Influence 
 
10. Provide information about peer behavior (Peer passive). The mHealth app 
provides information about what other cancer survivors do and think in relation to 
targeted behavior change.   This can be provided in the form of written anecdotes 
YouTube videos and may be presented as interviews or case studies.  
 
11. Provide opportunities for social comparison (Peer active) The mHealth app offers 
participation in Facebook, Twitter or other social media and networking in which 
discussion and social comparison may occur.  The focus is on providing social reference 
for the behavior change or activity.  Only score this technique when examples of group 
or peer discussion including personal stories of behavior are shared.  For example, a 
participant cancer survivor shares that “setting my own goals for physical activity and 
sharing those with my Facebook friends really helped me make my goals.”   Or, ”writing 
down my concerns about pain helped me communicate more effectively with my 
doctor.”  
 
12. Mobilize Social Norms (Important Others) The mHealth app provides exposure to 
the social norms of important others in relation to a healthy survivorship activity or 
health behavior change.  Important others may be valued and trusted experts such as a 
recognized healthcare professional, a celebrity cancer survivor or a recognized cancer 
survivorship researcher or advocate (e.g., Nancy Brinker of Susan G. Komen for the 
Cure or Cathy Giusti, founder of the Multiple Myeloma Research Foundation 
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Table C.1 iOS and Android App Scoring Sheet  
 
Application Name   Source 
iOS 
Phone 
iOs 
iPad 
Androi
d  
Coder          
Determinant Number Technique 
Coding 
(1/0)       
General Techniques             
1 Personalization 1           
2. Tailoring  2.1 Macro-tailoring         
(note may be all 3)  2.2 Meso-tailoring         
  2.3 Micro-tailoring         
3.Knowledge/Awareness 3.1 
Health behavior 
linkage         
  3.1a Personalized         
  3.1b Tailored         
  3.2 
Action/behavior 
consequences          
4.Intention  4 
Prompt for 
Intention 
Formation         
              
5. Facilitation  5.1 
Provide 
Instruction         
  5.2 
Materials for 
Education         
6. Goal Setting  6.1 
Prompt for 
Specific Goals         
  6.2 
Review of Goal 
Activity         
7. Self Efficacy 7 
Self Monitoring 
of Goals         
8. Feedback on 
Performance 8 
Feedback or 
evaluation of 
goals         
 
 
  143
Table C.1 Continued 
 
9. Persuasion  9.1 
General 
Persuasion         
  9.2 
Tailored 
Persuasion          
10. Social Influence 10.1 
Information on 
Peer Behavior 
(passive)         
  10.2 
Opportunity for 
Social 
Comparison         
11. Mobilize Social 
Norms 11 
Exposure to 
Important 
Others          
 
 
Table C. 2 iOS Apps and URLs 
 
 
iOS App 
Name  URL  
AYA Cancer 
Survivorship  
https://itunes.apple.com/us/app/aya-healthy-
survivorship/id513642187?mt=8 
Pocket 
Cancer Care 
Guide  
https://itunes.apple.com/us/app/pocket-cancer-care-
guide/id453059212?ls=1&mt=8 
Cancer 101 https://itunes.apple.com/us/app/cancer-101/id634255819?mt=8 
My Cancer 
Coach https://itunes.apple.com/us/app/cancer-coach/id468322618?mt=8 
Cancer 
Defeated https://itunes.apple.com/us/app/cancer-defeated/id734799886?mt=8 
Cancer 
Quotes https://itunes.apple.com/us/app/cancer-quotes/id633379119?mt=8 
Cancer Risk 
Reduction https://itunes.apple.com/us/app/cancer-risk-reduction/id525906303?mt=8 
Cancer 
Treatment 
Support 
https://itunes.apple.com/us/app/cancer-treatment-
support/id529556518?mt=8 
Cancer.net 
Mobile https://itunes.apple.com/us/app/cancer.net-mobile/id433501257?mt=8 
Cancer 
Discover 
Your Healing 
Power 
https://itunes.apple.com/us/app/cancer-discovering-your-
healing/id499076412?mt=8 
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iOS App 
Name URL  
Cancer Care https://itunes.apple.com/us/app/cancercare/id322892401?mt=8 
Cancer 
Defense https://itunes.apple.com/us/app/cancerdefense/id489556956?mt=8 
Cancer Late 
FX https://itunes.apple.com/us/app/cancerlatefx/id725634267?mt=8 
Cancer 
Zapper https://itunes.apple.com/us/app/cancer-navigator/id738587966?mt=8 
Cancer 
fighter https://itunes.apple.com/us/app/cancer-zapper/id441135097?mt=8 
Breacan 
Navigator https://itunes.apple.com/us/app/cancerfighter/id508348299?mt=8 
Breast 
Cancer Your 
Personal 
Assistant https://itunes.apple.com/us/app/breacan-navigators/id715478052?mt=8 
Breast 
Cancer 
Treatment 
Summary 
https://itunes.apple.com/us/app/breast-cancer-your-
personal/id636462141?mt=8 
Colon Cancer 
(iPad) https://itunes.apple.com/us/app/childhood-cancer-facts/id550933125?mt=8 
Kidney 
Cancer https://itunes.apple.com/us/app/colon-cancer-for-ipad/id815572678?mt=8 
Lung Cancer 
Handbook https://itunes.apple.com/us/app/kidney-cancer/id363469578?mt=8 
Lymphedema 
App https://itunes.apple.com/us/app/lung-cancer-handbook/id675750229?mt=8 
Prostate 
Cancer 
Educated 
Patient https://itunes.apple.com/us/app/lymphtracker/id555832934?mt=8 
Prostate Pal https://itunes.apple.com/us/app/prostate-cancer-
treatment/id713615914?mt=8 
 
Table C. 3 Android Apps and URLs 
Android App 
Name  URL  
Breast 
Cancer 411 
https://play.google.com/store/apps/details?id=com.appmakr.app381412&hl
=en 
Lung Cancer 
411 
https://play.google.com/store/apps/details?id=com.appmakr.app381393&hl
=en 
Breast 
Cancer  
https://play.google.com/store/apps/details?id=com.a16239921575042ebe1
deeba8a.a17836414a&hl=en 
Ask the 
Nutritionist  https://play.google.com/store/apps/details?id=org.danafarber.recipes&hl=en 
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Android 
App Name  URL 
My Breast 
Cancer 
Team 
https://play.google.com/store/apps/details?id=com.myhealthteams.MyBC
Team&hl=en 
CML 
Tracker/Rec
order  https://play.google.com/store/apps/details?id=air.com.cml.recorder&hl=en 
Befitting You https://play.google.com/store/apps/details?id=com.app_bfy.layout&hl=en 
Cancer.net 
Mobile https://play.google.com/store/apps/details?id=com.fueled.cancernet&hl=en 
Cancer https://play.google.com/store/apps/details?id=com.historia.cancer&hl=en 
Sign 
Guidelines 
(132) https://play.google.com/store/apps/details?id=com.rootcreative.sign&hl=en 
Cancer 
Coach 
https://play.google.com/store/apps/details?id=com.genomichealth.CancerC
oach&hl=en 
Esophageal 
Cancer Care  
https://play.google.com/store/apps/details?id=com.a1783027583500afc062
78009a.a35570151a&hl=en 
ESMO 
Guidelines 
https://play.google.com/store/apps/details?id=com.appyzz.android.esmo&hl
=en 
Re-Mission  https://play.google.com/store/apps/details?id=air.com.rm2.nbr&hl=en 
Breast 
Cancer 
Updates 
https://play.google.com/store/apps/details?id=com.phonegap.breastcancer&
hl=en 
Breast 
Cancer 
Awareness 
https://play.google.com/store/apps/details?id=com.magna.srior.breastcance
r&hl=en 
Prostate 
Cancer 
Calculator https://play.google.com/store/apps/details?id=com.borinfer.test&hl=en 
Liver Cancer 
411 
https://play.google.com/store/apps/details?id=com.appmakr.app381467&hl=
en 
Prostate Pal 
https://play.google.com/store/apps/details?id=com.quarkstudios.prostatep
al&hl=en 
Navigating 
Lung Cancer 
https://play.google.com/store/apps/details?id=com.realintelligence.BJALu
ngC&hl=en 
Focus on 
Lymphoma https://play.google.com/store/apps/details?id=com.acrosshealth&hl=en 
Testicular 
Cancer 
https://play.google.com/store/apps/details?id=com.a5997895965034aaf7
cc5469a.a56473555a&hl=en 
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CANCER.GOV http://m.cancer.gov/ 
Play to Cure: 
Genes In 
Space 
https://play.google.com/store/apps/details?id=com.guerillatea.elementalp
ha&hl=en 
Lymphedema 
Breast Cancer 
App 
https://play.google.com/store/apps/details?id=com.kellylymphoedemabre
astcancerapp.com.au.Lymphoedema_Breast_Cancer_App&hl=en 
CANCER 
SMASHER!! 
https://play.google.com/store/apps/details?id=org.example.cancersmashe
r&hl=en 
Cancer Fighter 
https://play.google.com/store/apps/details?id=com.NewHopeGames.canc
erfighter&hl=en 
Cancer 
Blockade 
https://play.google.com/store/apps/details?id=com.bodyxq.cancerblockad
e2&hl=en 
Lite Match3 for 
Breast Cancer 
https://play.google.com/store/apps/details?id=AKnght.Studios.CureLite&h
l=en 
Hit Cancer for 6 
as Yuvi 
https://play.google.com/store/apps/details?id=com.pecs.playwithyuvi&hl=
en 
Stop Cancer https://play.google.com/store/apps/details?id=com.triton.stop&hl=en 
Re-Mission2: 
Nanobot's 
Revenge https://play.google.com/store/apps/details?id=air.com.rm2.nbr 
 
 
 
 
 
 
 
 
 
 
 
 
